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ABSTRACT 
 
The Role of Alpha-Hemoglobin Stabilizing Protein in Human  
Hemoglobin Assembly 
 
by  
 
Todd L. Mollan 
 
 
Hemoglobin biosynthesis in erythrocyte precursors involves several steps. 
The correct ratios and concentrations of normal alpha (α) and beta (β) globin 
proteins must be expressed, apoproteins must be folded correctly, heme must be 
synthesized and incorporated into these globins, and the resulting α and β 
subunits must be rapidly and correctly assembled into heterotetramers. These 
events occur on a large scale in vivo, and dysregulation causes serious clinical 
disorders such as thalassemia syndromes. Recent work has implicated a 
conserved erythroid protein known as Alpha-Hemoglobin Stabilizing Protein 
(AHSP) as a participant in these events. Current evidence suggests that AHSP 
enhances α subunit stability and diminishes its participation in harmful redox 
chemistry. There is also evidence that AHSP facilitates one or more early-stage 
post-translational hemoglobin biosynthetic events. In this work, the rate 
constants associated with AHSP binding to and dissociation from native ferric 
and ferrous human α subunits have been determined, along with the binding and 
dissociation equilibrium constants. Also, several mutant AHSP proteins were 
used to better define the cis-trans peptidyl-prolyl isomerization events that AHSP 
is known to undergo, and several naturally occurring human α subunit missense 
mutants were used to probe AHSP function. Additionally, several post-binding 
events regarding AHSP:α-subunit interactions were investigated, such as 
autooxidation, heme uptake, hemin loss, effects on ligand binding, and secondary 
structure acquisition. Finally, AHSP was co-expressed with α and β subunits in 
transgenic Escherichia coli as a way of probing the effects of AHSP on 
hemoglobin production. Collectively, these data support the model that AHSP 
rapidly binds α subunits, stabilizes them, and then is displaced by β subunits 
during hemoglobin production. 
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Chapter 1: Introduction 
 
*Much of the prose, figures, and references that appear in this chapter were taken from 
Mollan et al. (1). The portions reproduced here were those that were composed by the 
first author of that publication, and quotation marks and further references to this 
work have been omitted to avoid redundancy. 
 
 
Significance 
In recent years, over 14 million units of allogeneic whole blood and red 
blood cells have been transfused annually into patients in the United States (2). 
These transfusions are often life-saving (3-5) and seldom cause adverse events 
(6-11). Unfortunately, U.S. hospitals have recently reported blood shortages 
that are predicted to worsen as the population ages (2, 12-16). Costly 
diagnostics and handling regulations, increasingly stringent donor deferral 
criteria, and diminishing rates of blood donation partly explain this problem 
(17-21). However, other issues such as emergent pathogens, natural disasters, 
wars, and adverse reactions from mistransfusions are also of concern (6, 17, 22-
31). These and other factors have led to a ―cost explosion‖ in the industry (6), 
with the price of one unit of packed red blood cells (PRBCs) significantly 
increasing in recent years (32-34). 
Many of these concerns can be addressed with recombinant hemoglobin-
based oxygen carriers (rHBOCs). These therapeutics consist of concentrated 
solutions of acellular human Hemoglobin A (HbA) which has been expressed in 
and isolated from transgenic organisms (35-39). They are similar to non-
recombinant HBOCs, which are a more well-studied class of therapeutics that 
are derived from animal erythrocytes or outdated units of human blood 
(reviewed in 6, 40-61). In principle, rHBOCs can be transfused in place of 
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PRBCs to facilitate dioxygen (O2) transport while offering the following 
advantages: (1) decreased immunopathology, (2) longer shelf-life, (3) 
diminished risk of disease transmission, (4) enhanced oxygen delivery, (5) 
controllable rheological and osmotic properties, (6) improved uniformity in 
composition, (7) higher purity, (8) more reliable availability, (9) fewer 
transfusion-induced adverse events, and (10) availability to patients who 
cannot receive conventional blood transfusions for personal, geographical, 
religious, or clinical reasons (50-52, 62, 63). Despite these advantages, 
regulatory approval has been limited thus far (presently, only one HBOC has 
been approved for human use in South Africa, with another being approved for 
veterinary use in the United States of America)(58, 60, 64). One of the main 
reasons for the lack of an approved HBOC is that transfusions of current-
generation products has in some cases led to adverse cardiovascular, 
cerebrovascular, and other harmful events (65). Another reason is that 
recombinant HBOCs which have been rationally designed to mitigate these 
adverse events are costly to investigate due to technological issues associated 
with their production. 
The main objective of this thesis has been to address several problems in 
HBOC research by obtaining a more thorough understanding of the post-
translational events associated with HbA production. This knowledge should 
put researchers in a better position to optimize the production of candidate 
rHBOCs which can then be evaluated as alternatives to PRBCs. Because the cost 
of recombinant HbA expression is currently a significant impediment to 
commercial development, overcoming this issue would be a major advance.  
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A second objective has been to generate a better understanding of the 
relationship between certain hematological disorders and HbA production. 
Although a great deal is known about normal and aberrant HbA production, our 
understanding of this process is incomplete, and work in this area is expected to 
inform treatment options and research regarding some of these disorders. 
Lastly, the determination of HbA assembly mechanisms will help expand our 
understanding of how other biologically important, multi-subunit proteins are 
produced in vivo. 
 
Hypothesis and Specific Aims 
The hypothesis for this work is that a putative molecular chaperone 
known as Alpha-Hemoglobin Stabilizing Protein (AHSP) assists with human 
HbA biosynthesis in vivo. The specific aims were: (a) to characterize the impact 
of this protein on HbA subunit assembly and to better define its function, and 
(b) to ascertain whether this protein can be used in rHBOC production to 
enhance heterologous expression yields of recombinant hemoglobin (rHb) in 
Escherichia coli (E. coli). 
 
Types, Occurrence, Overview of Human Hemoglobin 
Normal adult human blood contains approximately 12 to 15 grams (g) of 
hemoglobin (Hb) per 100 milliliters (mL) of fluid (66-68). This amounts to 
more than 600 g of Hb per person, assuming that the person is healthy and 
possesses a normal blood volume of approximately 5 liters (L)(67, 68). About 
92% of this abundant protein is a subtype of Hb that has been designated 
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Hemoglobin A (HbA)(66). HbA belongs to a class of highly conserved and 
functionally diverse proteins whose evolution can be traced back for at least 1.8 
billion years (reviewed in 69-82). In humans, this protein has been shown to be 
responsible for O2 transport (reviewed in 83-86). It has also been shown to play 
a role in carbon dioxide (CO2) transport, blood pH and redox chemistry 
regulation, and vasoregulation through chemical reactions involving nitric 
oxide (NO)(reviewed in 66, 87-102). 
Structurally, HbA is a 64,500 ± 100 Dalton (Da) tetrameric protein 
which consists of two alpha (αH) chains and two beta (βH) chains (Figure 1-1A) 
(103). Each chain consists of helical and non-helical sections, with αH chains 
possessing seven α helices and βH chains possessing eight (104-107). The 
helices within each chain are referred to by convention using the letters A 
through H, with αH chains lacking a D helix (Figure 1-1B, C)(107). Within each 
chain, there is a single, iron-containing protoporphyrin IX group (―heme‖ in the 
case of ferrous (II) iron; ―hemin‖ in the case of ferric (III) iron)(66, 107). These 
groups are held in place by numerous interactions with the globin chain, 
including a covalent bond between the heme iron and the imidazole nitrogen of 
conserved histidines within each chain (66). This bonding occurs with His87 in 
αH chains and His92 in βH chains, both of which are referred to as the proximal 
histidines (Figure 1-1)(66, 107). The opposite face of each heme group (the 
distal side) is responsible for binding ligands such as alkyl isocyanides, carbon 
monoxide (CO), NO, and O2, as well as azide (N3-), cyanide (CN-), fluoride (F-), 
hydroxide (OH-), NO, and water (H2O) when the heme iron is oxidized to the 
ferric state (66, 108-112). 
5 
 
 
Figure 1-1. Structure of HbA 
Heme groups are shown as red stick structures, αH chains in gray 
ribbon structures, and βH chains in yellow ribbon structures. 
Proximal histidines are depicted using stick structures with Corey-
Pauling-Koltun (CPK) coloring. HbA is shown in Panel A, the α1β1 (or 
α2β2) interface in Panel B, and the α1β2 (or α2β1) interface in Panel C. 
The nature and extent of inter-subunit contacts change depending on 
whether the subunits are deoxygenated or have O2 bound. Figure 
generated using PyMOL Molecular Graphics System and PDB 1LFL 
(DeLano Scientific, Palo Alto, California, US)(113). 
The chains of each tetramer are held together through a series of non-
covalent bonds, mostly apolar, which make up two types of inter-subunit 
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interfaces (107). Those involving the B, G, and H helices and the GH corner 
from each subunit are called α1β1 (or α2β2) interfaces (Figure 1-1B)(107). Those 
involving the C and G helices and the FG corner from each subunit are called 
α1β2 (or α2β1) interfaces (Figure 1-1C)(107). Within each HbA tetramer, there 
are a total of four interfaces: (1) α1β2, (2) α2β1, (3) α1β1, and (4) α2β2. There is 
little, if any, direct α-α or β-β chain contact within HbA tetramers (105, 107). 
In humans, HbA is produced from three genes: two α globin genes and 
one β globin gene per haploid genome (HBA1 and HBA2 on Chromosome 16, 
NCBI Accession NM_000558.3 and NM_000517.4; and HBB on Chromosome 
11, NCBI Accession NM_000518.4)(114, 115). HBA1 and HBA2 each code for 
the same α globin protein, which is 141 residues long and has a molecular mass 
of 15,126.7 ± 1.4 Da without its heme group (NCBI Accession NP_000549.1, 
NP_000508.1)(114, 116). HBB encodes β globin, which is a 146-residue-long 
protein with a molecular mass of 15,867.4 ± 0.7 Da without heme (NCBI 
Accession NP_000509.1)(114, 116). The molecular genetics and regulatory 
programs coordinating the expression of these genes are complex (reviewed in 
117-127). Moreover, there are over 1,000 mutations which are known to affect 
the expression and/or functional properties of these genes and their products 
(128). 
HBA1, HBA2, and HBB are situated within a cluster of other globin 
genes which are differentially expressed as part of a developmental process 
called globin switching (reviewed in 117, 119, 129-132). Part of this work 
involves the study of human fetal Hb (HbF), which is a type of Hb that is 
produced during this process. HbF is present in small amounts in healthy 
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human adults (<1% of the total Hb in circulating erythrocytes) and in large 
amounts in embryos and fetuses beginning at about six weeks post-fertilization 
(>75% of total Hb)(66, 131). By about 18 weeks post-birth, HbF expression is 
appreciably diminished (66, 131). 
 
Figure 1-2. Structure of HbF 
The color scheme, ribbon and stick forms used in this 
figure are the same as those used in Figure 1-1, except 
that γH chains appear in purple. Figure generated using 
PyMOL Molecular Graphics System and PDB 1FDH 
(DeLano Scientific, Palo Alto, California, US)(133). 
 
Like HbA, HbF is a tetramer, with each subunit bearing a single heme or 
hemin group (Figure 1-2)(133). HbF is functionally very similar to HbA, and it 
is thought to act primarily as an O2 transport protein that is adapted for O2 
uptake in the placenta (66, 134). The major difference is that instead of 
possessing two αH and two βH chains, HbF possesses two αH and two gamma 
(γH) chains (Figure 1-2). The primary amino acid sequence of γH chains differs 
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from that of βH chains at 36 positions (66). Also, there are two γ globin genes 
on Chromosome 11, designated Aγ and Gγ globin, which code for 146-residue-
long proteins that differ at position 136 of their primary sequences (HBG1 and 
HBG2, NCBI Accession NM_000559.2, NM_000184.2, P69891.2, 
NP_000175.1)(114, 115). 
 
Post-Translational Pathways of HbA Biosynthesis 
A great deal of information is known about the structural biology and 
physiology of HbA and its various mutants (66, 107, 135, 136). However, much 
less is known about certain post-translational events that occur during HbA 
production in vivo. These events include HbA subunit folding, heme or hemin 
binding, and assembly into functional heterotetramers. Previous work on these 
processes has left many open questions regarding how they fit together in vivo, 
and several alternate pathways for HbA production may co-exist in mammalian 
pre-erythroid cells. 
The first steps of HbA production involve HBA1, HBA2, and HBB gene 
translation, which takes place on the order of a few minutes per subunit (137-
141). Given that α helices and certain other structural features are capable of 
forming spontaneously and in less than a few microseconds (142-145), it is 
plausible to conclude that α and β chains acquire at least some of their 
secondary and tertiary structure co-translationally. Several studies using cell-
free protein expression systems have supported this idea, and have further 
indicated that heme or hemin insertion is also a co-translational process (136, 
146, 147). However, not everyone agrees on the timing of these events, and 
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several researchers have reported that heme- or hemin-free α and β globins (αO 
or βO globins) only acquire their prosthetic groups after first dissociating from 
ribosomes (148-151). 
In vitro work suggests that the rate constants associated with prosthetic 
group binding to and dissociation from α and β chains are nonequivalent (152-
157). These values are dependent not only on which amino acids line the globin 
binding pockets, but also on whether the globins are monomeric or oligomeric, 
and whether they are in complex with heme-containing or heme-free subunits 
(152-163). The reaction of reduced CO-heme with heme-free αβ dimers (αOβO 
dimers; apodimers; apoglobin) is rapid and spontaneous, occurring with rate 
constants on the order of 107 to 108 M-1s-1 (164-167). The rates for hemin 
binding are less well defined, most likely because free hemin aggregates in 
solution and complicates kinetic analyses (153, 164, 168, 169). In contrast, heme 
loss occurs at almost immeasurably slow rates (156, 170). These rates increase 
upon oxidation of the iron to the ferric state, and the observed rates range from 
0.3 and 40 hr-1 in pH 7.0 buffer at 37 OC, depending on the particular subunit 
and quaternary state under investigation (155). 
Figure 1-3 provides an overview of heme and hemin binding to and 
dissociation from HbA and its subunits. Although the equilibrium constants 
associated with these events are not known with certainty, it is clear that HbA 
and its subunits have a higher affinity for heme than for hemin. Moreover, 
heme binding has been linked to helicity increases (18% to 65% in α chains; 
51% to 65% in β chains)(171), and inter-subunit association events cause 
increases in both secondary and quaternary structure (155, 171-175). 
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Figure 1-3. Prosthetic group binding to HbA and its 
subunits 
Heme insertion rates were measured in 50 mM Tris, 50 mM NaCl, 
pH 8.0 at 20 OC, and hemin loss rates in 150 mM potassium 
phosphate buffer with 450 mM sucrose, pH 7.0 at 37 OC. Colors, 
ribbons, and stick forms are the same as in Figure 1-1. Figure 
generated using PyMOL Molecular Graphics System and PDB entry 
1LFL (DeLano Scientific, Palo Alto, California, US)(113, 153, 155, 156, 
164, 171-173). 
In vitro reconstitution studies of HbA suggest that its formation occurs 
through a series of monomeric, dimeric, and tetrameric intermediates that are 
partially saturated with heme (175-178). Some workers have suggested that αH 
chains drive heme insertion into βO globins following αHβO dimer formation 
(161, 179, 180). Consistent with this hypothesis, αO chains have been shown to 
have a higher affinity for heme than βO chains (152, 160, 164, 174, 175, 177, 178, 
181). Also, both αO and αH chains have been reported in their monomeric forms 
in vivo, and free βH chains tend to be absent except in cases of severe α 
thalassemia (161). Although these observations are consistent with the idea that 
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αH chains are the primary drivers of HbA formation, several other plausible 
models exist. 
Isolated βO chains are known to possess more well-defined structural 
features than αO chains (182, 183), and β4H tetramers can form once heme 
binding occurs (184, 185). This evidence supports the observation that isolated 
β chains are more stable than isolated α chains in solution (186), and suggests 
an assembly model in which βH chains self-chaperone and drive heme insertion 
into and folding of αO chains. Alternatively, the assembly of partially folded αO 
and βO subunits into more fully folded αOβO globin dimers could drive heme 
uptake into both subunits. In support of this idea, the removal of heme from 
HbA results in αOβO globin dimers, and dissociation into monomeric αO and βO 
subunits leads to the immediate precipitation of both subunits at temperatures 
above 5° C (171-173). Although isolated and partially unfolded αO and βO 
subunits do not readily recombine to form αOβO globin dimers in vitro (171, 
172), indirect in vivo evidence for the existence of this dimeric species has been 
reported in some studies (148-150). 
Figure 1-4 depicts several plausible pathways regarding these events. 
Although there are a great deal of data, there is presently little consensus 
regarding the exact sequence of in vivo events. 
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Figure 1-4. Pathways of folding, heme insertion, subunit assembly 
The most likely pathways for HbA production are summarized in this figure. Not 
depicted is the role of AHSP, which is discussed later. Also not shown is the possibility 
that heme insertion into one chain drives other events, or that any of these events 
might occur co-translationally. Colors, ribbons, and stick forms are the same as in 
Figure 1-1, except the use of thin lines and ribbons for the backbone structures 
indicates unfolded and folded states, respectively. Figure generated using PyMOL 
Molecular Graphics System and PDB entries 1CBM and 1LFL (DeLano Scientific, Palo 
Alto, California, US)(187, 188). 
In contrast to folding and heme insertion events, the association of 
isolated αH and βH chains to form intact tetramers in solution has been studied 
extensively and presents a clearer picture (150, 165, 166, 171-173, 184, 185, 189-
205). When mixed together in vitro and at low concentrations (<10 µM), αH and 
βH chains spontaneously associate with each other to form HbA as part of a 
two-step process. First, monomeric αH and βH chains associate to form αH1βH1 
dimers, then two of these dimers associate to form tetrameric HbA (190, 191, 
200, 201, 206). The observed bimolecular association rate constants for both of 
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these steps are approximately 5 x 105 M-1s-1 for deoxygenated subunits (190, 
193, 201). Because of similarities between the deoxy-, carbonmonoxy-, and oxy-
states of HbA at the αH1βH1 interface, the rate constants for α1β1 (or α2β2) bond 
formation are likely to be independent of ligand state (196, 205). The same 
cannot be said of the α1β2 and α2β1 interfaces, which exhibit significant 
alterations depending on whether they have ligands bound (196, 205). It has 
been shown that in the absence of O2, for example, tetramer dissociation into 
αH1βH1 dimers is several orders of magnitude slower than when O2 is bound 
(196, 197, 204). 
An additional detail regarding subunit assembly is that isolated βH 
chains readily form homotetramers (βH4) at subunit concentrations ≥10 µM (KD 
≈ 10-15 to 10-17 M3)(184, 185), whereas αH chains remain monomeric at subunit 
concentrations ≤100 µM (KD ≈ 10-4 M)(184, 194). Thus, the assembly of HbA 
involves three steps when subunit concentrations are high. First, βH4 tetramers 
dissociate into βH chain monomers, which occurs with rate constants of 
approximately 0.25 s-1 to 0.001 s-1, depending on the concentration of inorganic 
or organic phosphates present (201). Then, the two association events to form 
HbA tetramers occur (190, 200, 201, 206). 
Figure 1-5 contains a summary of rate constants for these events. It is 
important to note that the overall reaction sequence described here is the same 
for oxygenated and deoxygenated subunits (200), but that recorded values 
suggest that the rate of flux through these pathways is ligand-modulated. Also, 
in the first bimolecular associative step, it is important to note that α and β 
subunits combine to form the α1β1 interface, which involves extensive 
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hydrophobic and some electrostatic interactions between the B, G, and H 
helices and the GH corner from each subunit (Figure 1-1B). Then, these dimers 
associate in the second bimolecular step to form two new interfaces, the α1β2 
and α2β1 interfaces, which are less extensive and involve more polar 
interactions (Figure 1-1C)(66, 104, 105, 107, 206, 207). 
 
Figure 1-5. Inter-subunit interactions 
Rate constants were measured using comparable buffer conditions (pH ~7 at ~22 OC, 
buffered by 50 to 150 mM phosphate, with excess sodium dithionite). Colors, ribbons, 
and stick forms are the same as those used in Figure 1-1. Figure generated using 
PyMOL Molecular Graphics System and PDB entries 1LFL and 1CBM (DeLano 
Scientific, Palo Alto, California, US)(113, 184, 185, 188, 196-199, 201-205). 
 
Heterologous Expression of Recombinant HbA 
Experiments dealing with the heterologous expression of recombinant 
HbA using transgenic organisms first began in the 1980s. Transgene 
overexpression in E. coli and S. cerevisiae was accomplished with expression 
levels exceeding ~5% of total cellular protein content (208-214). Subsequent 
developments in animals led to the development of transgenic pigs which 
expressed up to 32 grams of human hemoglobin per liter of whole blood 
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hemolysate, amounting to ~24% of the total Hb content in the pig erythrocytes 
(215). Although rHb production has now been achieved in numerous 
organisms, including mice, tobacco plants, and insect cells, most work has 
focused on expression in E. coli (39, 179, 208-210, 212-214, 216, 217, 217, 218, 
218-223, 223-251). Many significant advancements have been made in this 
system during the last two decades (reviewed in 247-276). 
In the early 1980s, it was shown that β subunits from human HbA could 
be expressed in and isolated from bacteria (277-279). Subsequent work revealed 
that these recombinant β subunits could be reconstituted with native αH 
subunits to produce functional tetrameric rHb (277, 280). Individual apoglobin 
expression was later accomplished for α subunits (228, 281-283). These early 
efforts utilized a cleavable lambda (λ) phage leader sequence designed to inhibit 
bacterial proteolysis and increase expression levels. Protocols involved 
preparative protein refolding of insoluble aggregates in the presence of heme, 
as well as leader sequence cleavage and removal prior to subunit recombination 
to form HbA. Investigators subsequently developed more refined methods 
which did not involve all these steps (211, 213, 216, 217, 225, 226, 250, 251, 284-
287). In recent years, several groups have begun exploring the use of non-
human Hbs as an rHBOC source material. For example, Hbs from Bos taurus 
and Arenicola marina are being investigated for this purpose (288-295). 
In the 1990s, significant commercialization efforts culminated in the 
development of two rHBOCs which reached late stage-clinical trials before their 
development was halted due to costs associated with conducing further 
necessary research (rHb 1.1 and rHb 2.0; Somatogen Incorporated, 
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subsequently acquired by Baxter International Incorporated)(58, 64). At that 
time, significant efforts were underway to understand the side effects associated 
with transfusing unmodified acelluar HbA into humans. These side effects 
include: (1) nephrotoxicity with complex underlying causes (50, 296-313), (2) 
rapid clearance by the kidneys, reticuloendothelial system, and other 
mechanisms (t½ < ~1 hour)(187, 299, 314-331), (3) significantly altered O2 
affinity and offloading characteristics (54, 55, 332-355), and (4) side effects 
such as adverse immune reactions, vasoconstriction, gastrointestinal distress, 
neurotoxicity, perturbed retinal morphology, reduced cardiac output, increased 
systemic and pulmonary vascular resistance, coagulation events, redox 
dysregulation, and other events that appear to be associated with interference 
with NO signaling in smooth muscle (42, 296, 306, 356-406). Other problems 
include issues related to colloid osmotic pressure and viscosity differentials 
between PRBCs and acellular HbA (306, 407-433). 
Another key problem is rHBOC production efficiency. The most up-to-
date expression systems require about 750 L of log-phase bacterial culture to 
produce one unit of blood (56). Moreover, ―… 2 units of [recombinant Hb] at 
$700 to $1000 per unit have a similar Hb content to a single unit of donated 
blood at $200‖ (62), and trauma care patients often each require an excess of 
10 units of PRBCs following acute and severe injuries (434, 435). Animal-
derived Hb might seem like a more cost-effective rHBOC source material, given 
that one cow can be killed to provide 40 units of blood (61). However, it is 
expensive and time-consuming to produce transgenic livestock, and making 
genetic changes to rHbs in these systems requires developing entirely new lines 
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of animals, as opposed to simply mutagenizing a bacterial plasmid. At present, 
the greatest need is to inexpensively produce mid-sized batches of rationally 
designed rHBOCs which can be utilized in pre-clinical animal studies to address 
toxicity issues. 
 The most advanced E. coli-based rHb expression systems involve one- 
or two-plasmid ensembles which co-express codon-optimized α and β globin 
genes along with other proteins such methionine aminopeptidase (MAP) and, 
in some cases, hemin transporters (39, 211, 216, 436-439). An additional 
approach to bolstering rHb expression yields is to use the putative molecular 
chaperone AHSP (440-442). However, in order to assess the usefulness of this 
approach, AHSP must first be well characterized and its role as a chaperone 
established quantitatively. 
 
Overview of AHSP 
Several individuals examining AHSP have suggested that this protein is a 
molecular chaperone which participates in HbA production (442-445). A 
molecular chaperone is a protein ―... that binds to and stabilizes an otherwise 
unstable conformer of another protein—and by controlled binding and release 
of the substrate protein, facilitates its correct fate in vivo: be it folding, 
oligomeric assembly, transport to a particular subcellular compartment, or 
controlled switching between active/inactive conformations‖ (446). This class 
of proteins is large, diverse, and well-studied (447-454). Although AHSP is 
conserved among diverse vertebrates, it shares no sequence motifs with any 
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other known proteins, chaperones or otherwise (443). Figure 1-6 contains 
primary sequence information regarding AHSP. 
AHSP was discovered from experiments on transmissible spongiform 
encephalopathies (TSEs)(455, 456). TSEs are serious neurological diseases 
caused by ―epigenetic templated protein misfolding‖ (457), and were initially 
identified in the early 1980s (reviewed in 458). In 2001, a study was published 
in which researchers sought to identify molecular markers useful for diagnosing 
these diseases and AHSP was discovered (456). The ahsp gene codes for a 102-
residue-long protein that was initially named Erythroid Differentiation Related-
Factor (EDRF) because it was found in erythroblasts and bone marrow (another 
designation for AHSP is Erythroid-Associated Factor (ERAF))(455, 456). 
Concurrent work directed by Mitchell J. Weiss at the University of Pennsylvania 
resulted in the independent discovery of this protein, which has subsequently 
become known as AHSP on the basis of its apparent function (443, 444). 
The characterization of AHSP began following a screen for downstream 
targets of GATA-1 (443). GATA-1 is a member of the highly-conserved GATA 
family of zinc-finger transcription factors (TFs) (reviewed in 459-461). As ―... 
one of the primary determinants of the erythroid lineage‖ (462), GATA-1 has 
specifically been shown to be critical to erythropoiesis (463, citing 464). Due to 
the complexity of signaling pathways involving this TF, Weiss and co-workers 
hypothesized that there may be unknown GATA-1 targets (443). Using  
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Figure 1-6. Human AHSP sequence information 
Panel A depicts the human ahsp gene cDNA and its translated product (NCBI 
Accession NM_016633.2)(114). Aromatic residues which give rise to the spectral 
properties discussed in Chapter 3 are highlighted in yellow, and the three α helices of 
this protein are highlighted in blue. Panel B lists other organisms whose genomes 
indicate the existence of AHSP protein. Searches using ahsp mRNA, cDNA, and 
translated protein sequences using different algorithms, parameters, and databases 
suggest that AHSP homologs are absent from known arthropod, invertebrate, fungal, 
and microbial genomes (bacterial, archaeal, eukaryotic microbes). Sequence 
translation and analysis was performed using tools available from the ExPASy (Expert 
Protein Analysis System) proteomics server at the Swiss Institute of Bioinformatics 
(SIB), available http://expasy.org/tools/, accessed January 6, 2011. Genome searches 
were performed using data and the Basic Local Alignment Search Tool (BLAST), both 
available at NCBI, http://blast.ncbi.nlm.nih.gov/, accessed January 6, 2011. 
 
subtractive hybridization and a GATA-1 null mutant erythroid cell line (465-
467), they identified AHSP as a novel GATA-1 target that is expressed in 
hematopoietic tissues (443). 
Glutathione-S-transferase (GST) pulldown and cellulose acetate 
electrophoresis revealed that AHSP associates with αH chains, but not βH chains 
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or HbA (443). Also, HbA forms as βH chains are titrated into solutions of AHSP 
and αH chains, and Western blotting showed that AHSP does not remain bound 
to the HbA complexes following the titration (443). Gel filtration elution 
profiles reported in another study corroborate these findings by showing that 
AHSP elutes independently from αH and βH chains in solutions containing all 
three components (444). Also, Wright-Giemsa and crystal violet staining of 
murine cells suggested that AHSP inhibits Hb inclusion body formation in vivo 
(443). 
Weiss and co-workers initially reported that AHSP expression increases 
incrementally during HbA biosynthesis in erythroid precursor cells (443), a 
finding which was subsequently confirmed by real-time quantitative PCR (468). 
To further investigate AHSP function, AHSP-/- and AHSP+/- mutant mice were 
generated and compared to wild-type animals (469). All three genotypes were 
indistinguishable by gross examination at birth (469). However, many null 
mutant mice had morphologically atypical and anemic erythrocytes, and some 
showed elevated reticulocyte counts (469). There were also inclusion and Heinz 
bodies (denatured globin chains) in the mutant mice erythrocytes (469). 
Although there was no evidence of HbA subunit precipitation in wild-type 
animals, AHSP+/- mice showed αH chain precipitation, and AHSP-/- mice 
showed both αH and βH chain precipitation (469). This latter finding was 
unexpected because previous work suggested that AHSP does not interact with 
βH chains (469). It was hypothesized that homozygotic disruption of AHSP 
creates a surplus of monomeric αH chains which then catalyze oxidative 
reactions that lead to HbA and αH and βH chain precipitation (469). 
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Extensive erythrophagocytosis and a diminished circulation half-life of 
erythrocytes were also observed in mutant mice (469). Mutants also exhibited 
enlarged spleens and preerythroid hyperplasia in both splenic and bone 
marrow tissues (469). Cell surface markers unique to specific developmental 
stages and flow cytometry revealed an abnormally high ratio of immature to 
mature erythrocytes in mutant mice (469). There was also elevated apoptosis in 
mutant animal hematopoietic tissues (469). On the basis of these findings, 
Weiss and co-workers concluded that abrogation of AHSP is harmful to both 
immature and mature erythrocytes, even though AHSP exists in lower 
concentrations in the latter cells (443, 469). 
Mackay and co-workers at the University of Sydney utilized circular 
dichroism (CD) spectroscopy, analytical ultracentrifugation, and analytical size-
exclusion gel filtration chromatography to study several biophysical properties 
of AHSP (444). CD spectra strongly suggested that AHSP consists principally of 
α helices, and analytical ultracentrifugation indicated that it exhibits an 
apparent molecular weight in the 11,200-11,800 range and exists as a monomer 
in solution (444). The stoichiometry of the association of AHSP with αH chains 
was studied by mixing different ratios of these proteins together and analyzing 
the resulting solutions by gel filtration chromatography (444). These 
experiments demonstrated a 1:1 stoichiometry between AHSP and αH chains, 
and indicated that AHSP is also capable of binding αO globins (444). They also 
suggested tight binding, which was confirmed by isothermal titration 
calorimetry (the association equilibrium constant was measured to be 1.0 x 107 
M-1 at 20 OC)(444). 
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In 2004, Santiveri et al. (470) determined the structure of AHSP using 
nuclear magnetic resonance (NMR) spectroscopy. This structure is shown in 
Figure 1-7. Initial data suggested that AHSP exhibits conformational 
heterogeneity as a result of cis-trans isomerization about the Asp29-Pro30 
peptide bond (470). To further investigate this point, a P30A mutant of AHSP 
was constructed to prevent isomerization (470). This mutant facilitated a 
determination of the three-dimensional solution structures for both (cis)AHSP 
and (trans)AHSP. It was found that the wild-type protein occupies only one 
conformation upon binding to αH chains, but in the absence of αH chains it 
exists in roughly equal populations of cis and trans conformers (470). Also, 
AHSP helices 1, 2, and the loop separating them constitute the binding interface 
in AHSP:αH-chain complexes (470). According to Santiveri et al., the three 
antiparallel α helices of AHSP are abnormally long and are arranged in a ―right-
handed twist‖ that has only been observed in one other protein, a prokaryotic 
ribosome recycling factor (470). 
These findings were extended in a subsequent study by Feng et al. (445), 
who determined the first crystal structure of AHSP by X-ray diffraction. The 
crystal structure was for a complex consisting of AHSP and (oxy)αH chains at 
2.8 Å resolution (445). In this structure, the G and H helices of αH chains were 
bound to AHSP helices 1 and 2 and the intervening loop. According to Feng et 
al.(445), the binding interface for these two proteins is similar to the αH1βH1 and 
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Figure 1-7. Cis and trans structural conformers of human AHSP 
Human AHSP is depicted in ribbon form with several residues of interest in stick form 
using CPK coloring. The import of these residues is explained in Chapters 3 and 5. 
Panel A depicts (cis)AHSP, Panel B depicts (trans)AHSP, and Panel C depicts the two 
conformers which proline adopts in AHSP (bottom), as well as an overlay of the two 
structures after their α carbons were aligned using the built-in PyMol alignment 
function (Top). Most structural differences between the two conformers exist in the 
loop separating helices 1 and 2, and in the C-termini of each conformer. Drawings were 
produced using the PyMol Molecular Graphics System and PDB entries 1W0A and 
1W09 (DeLano Scientific, Palo Alto, California, US)(470). 
 
αH2βH2 interfaces within HbA, except that αH1βH1 and αH2βH2 binding involves 
more extensive hydrogen bonding and shorter van der Waals distances than are 
present in AHSP:αH-chain complexes (445). These observations support the 
conclusion that the binding interface for AHSP:αH-chain complexes is 
―nonoptimal‖ (445), as well as the initial observation by Kihm et al. (443) that 
βH chains appear to displace AHSP from αH chains in solution when all three 
proteins are co-incubated. 
Feng et al. (445) also compared the heme pockets of αH chains in HbA 
with those in complex with AHSP, and discovered that the heme iron in 
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AHSP:αH-chain complexes is coordinated by His58 instead of His87. This is 
unusual because in HbA, His58 (the distal histidine) is not bound to the heme 
at all, and ligands such as O2 bind to iron on this side of the heme group (107). 
In the modified conformation of the crystal structure, however, ligands must 
bind to the opposite side of the heme if they bind at all. This alteration, along 
with several other changes within the binding pocket, were predicted to 
increase the heme group‘s exposure to solvent (445). Figure 1-8A depicts the 
structures reported by Feng et al. (445). 
Feng et al. (445) also showed that AHSP binding induces rapid oxidation 
of the heme iron of (oxy)αH chains. This finding was unexpected in light of 
previous work indicating that AHSP reduces the formation of reactive oxygen 
species (ROS) in vivo (445, 469). This apparent contradiction is resolved if 
AHSP drives the αH chain heme iron into a low-spin ferric state that does not 
permit further participation in oxidative reactions (445). Support for this idea 
was found in studies comparing absorbance and Raman spectra of αH chains 
and αH chains bound to AHSP. This work led to the hypothesis that AHSP locks 
αH chains ―... into an oxidized but fully liganded low-spin, non-reactive state‖ 
(445). Thus, according to the model presented by Feng et al. (445), the crystal 
structure of (oxy)αH chains complexed with AHSP represents a transition state 
that exists before the formation of a hexacoordinated, low-spin species that is 
unable to participate in ROS generation (445). 
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Figure 1-8. X-ray crystallographic structures of AHSP:αH-chain complexes 
Ferrous and ferric αH chains are shown in complex with either AHSP or βH chains. 
Panel A shows ferrous αH chains in complex with AHSP (top) and in complex with 
ferrous βH chains as part of the αH1βH1 interface (bottom). Note that the F-helix is 
disordered in the AHSP complex and that the distal histidine is bound to the heme iron 
instead of the proximal histidine (top). Panel B shows ferric AHSP:αH-chain complexes 
in two different orientations. Note that the hemin is coordinated by both the proximal 
and distal histidines in this state. AHSP appears in teal and hemin in olive, and the 
other colors, ribbon, and stick forms are the same as those used in Figure 1-1. The 
AHSP in these studies contained the P30A mutation, as well as a C-terminal truncation 
of 11 residues. Drawings were produced using the PyMol Molecular Graphics System 
and PDB entries 1Y01, 1Z8U, 1GZX (DeLano Scientific, Palo Alto, California, US)(445, 
471, 472). 
Seven months after the publication of the first crystal structure, another 
crystal structure was reported by these same investigators, along with several 
follow-up experiments (471). This report contained the structure of AHSP in 
complex with oxidized (that is, ferric) αH chains instead of ferrous αH chains 
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(471). Unlike the crystal structure of the oxygenated species, the ferric complex 
possessed a hexacoordinated hemin iron which was coordinated to both His58 
and His87 (a hemichrome, or bis-histidyl conformation)(Figure 1-8)(471). This 
hexacoordination involves significant structural alterations attributable to the 
secondary structures surrounding the hemin group, particularly the B, C, E, F, 
and H helices (471). These findings are consistent with the investigators‘ 
previous idea that such a hexacoordinated hemin might represent a 
―biochemically inert state‖ (445), because this conformation inhibits hemin-
H2O2 interactions (471). The hexacoordinated state of oxidized αH chains bound 
to AHSP was also confirmed by electron paramagnetic resonance (EPR) 
spectroscopy in a more recent paper, which also provided evidence that the 
formation of this structure occurs spontaneously under physiological conditions 
(473). 
Feng et al. (471) also assayed heme group sensitivity to oxidant damage 
by analyzing the decrease in Soret absorbance following exposure to H2O2. Also, 
tetramethyl-p-phenylenediamine (TMPD) and hydrogen peroxide were used to 
probe for redox reactions (471). Thus, both the impact of oxidants on the heme 
group and the impact of the heme group on oxidative reactions were observed 
as a function of heme iron coordination state. It was found that AHSP appears 
to diminish further heme iron oxidation by H2O2 and subsequent generation of 
oxidants. Also, it was shown by native gel electrophoresis that tetrameric 
hemoglobin can be formed using ferric AHSP:αH-chain complexes as precursors 
(471). 
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The Role of AHSP During HbA Biosynthesis 
There have been several studies of the impact of AHSP on rHb 
expression in E. coli-based heterologous protein production systems. One of the 
earliest efforts was reported by Marden and co-workers (441). They constructed 
a co-expression system which enables expression of either genetically fused 
GST-αH-chains alone or in conjunction with GST-AHSP (441). Biochemical 
analyses indicated that the αH chains purified using this system have properties 
almost identical to those of native αH chains (441). Using this system, AHSP 
was found to significantly enhance soluble αH chain production when the two 
proteins were co-expressed simultaneously in the presence of exogenously 
added hemin (441). When GST-αH-chains were expressed alone, exposing the 
cell lysates to GST-AHSP during cell disruption did not recover any insoluble 
αH chains that may have accumulated throughout the growth (441). The authors 
suggested that AHSP facilitates αH chain production by binding newly 
synthesized globin and facilitating folding and heme uptake (441). Their study 
demonstrates that AHSP acts to prevent αH chain aggregation, precipitation, 
and/or degradation, which is consistent with a molecular chaperone function. 
Weiss and co-workers subsequently provided further evidence for AHSP 
chaperone activity by investigating the adverse effects of ahsp gene disruption 
in mice (442). Given that a small pool of free αH chains is known to exist in 
erythroblasts (148, 474-479), it was hypothesized that the ill effects caused by 
ahsp gene disruption might be mitigated by lowering α globin gene dosage 
(442). This change would reduce or eliminate the pool of free αH chains that are 
unescorted by AHSP, and consequently might lessen the severity of the ahsp 
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knockout phenotype (442). The following strains of mutant mice were 
constructed to investigate this hypothesis: (a) mice lacking 1 of 4 α globin 
alleles (α globin*α/ αα), (b) homozygous null ahsp mice (ahsp-/-), and (c) ahsp-/-, 
α-globin*α/ αα double mutants (442).  
Surprisingly, the α globin*α/ αα mutation did not rescue the ahsp-/- 
phenotype, and the ahsp-/-, α-globin*α/ αα mice instead exhibited more severe 
phenotypes than mice carrying either mutation alone (442). Also, the mice 
possessing both mutations exhibited significant amounts of βH chain 
precipitation (442). As part of this work, Yu et al. (442) conducted a series of in 
vitro assays using recombinant AHSP. These assays showed that AHSP renders 
αH chains more resistant to trypsin digestion, and that it enhances HbA 
production yields in an in vitro wheat-germ transcription and translation 
system, possibly by facilitating αH chain folding (442). These findings suggest 
that AHSP is more than just a stabilizer of excess free αH chains and may be an 
active participant in HbA production. 
In a subsequent study, Dos Santos et al. (480) discovered that human 
ahsp gene expression is affected by the presence and absence of iron. They 
showed that the 3‘-end of ahsp mRNA contains a stretch of non-coding 
nucleotides that are predicted to form a stem-loop structure in solution (480). 
This sequence is similar to known iron responsive elements (IREs), and the 
investigators hypothesized that this stem-loop might interact with iron 
regulatory proteins (IRPs) in a way that makes ahsp gene expression iron 
dependent (480). Upon investigation, IRP-IRE interactions were confirmed, 
and it was shown that iron disrupts these interactions and results in the 
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destabilization of ahsp mRNA (480). By contrast, iron depletion using the 
chelator desferrioxamine had the opposite effect (480). These data strongly 
suggest that ahsp gene expression is upregulated when iron is scarce and 
downregulated when iron is abundant (480). These findings support the idea 
that AHSP stabilizes free αO globins which are known to build up when iron and 
heme are in short supply (480). Conversely, when intracellular iron and heme 
are abundant, there are fewer free α chains and therefore less of a need for 
AHSP, explaining IRE-mediated downregulation (480). 
Recently, Faggiano et al. (289) constructed an E. coli-based expression 
system which co-expresses AHSP with a human-bovine hybrid Hb (Hb 
Polytaur). Hb Polytaur is a ~500 kDa Hb consisting of human αH chains and 
bovine βH chains, both of which possess mutations designed to facilitate 
spontaneous self-polymerization by disulfide linkages (289). Interestingly, co-
expressing equal amounts of AHSP with this Hb results in decreased Hb 
expression yields (0.2 mg of Hb per L of medium, as opposed to 48 
mg/L)(289). This finding seems inconsistent with previous data regarding 
AHSP function. However, the authors note that ―...since Hb Polytaur is a hybrid 
globin, the contacts at the α-β interfaces are not as tight as they would be in the 
naturally occurring hemoglobins, resulting in a less effective ability of the β 
bovine chains to replace AHSP after binding to α human chains‖ (289). 
Figure 1-9 contains a summary of what is known about AHSP function. 
Yu et al. (442) have suggested that AHSP may play a role in αH chain folding 
and heme uptake. Such a role would be consistent with the observation that 
AHSP causes significant structural changes upon binding, particularly in the 
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area of the heme binding pocket. It is plausible that AHSP modulates the rates 
and affinities for heme or hemin binding to α chains. Alternatively, AHSP might 
ensure that heme is inserted in the correct orientation or that iron-free 
protoporphyrin IX is excluded from the binding pocket. Notably, AHSP and βH 
chains bind to αH chains at the same interface, making their interactions 
mutually exclusive, and AHSP must dissociate from αH chains before βH chains 
can bind. Thus, it appears that AHSP does not participate in the events that are 
downstream of αH1βH1 dimer formation, but instead acts as a competitive 
inhibitor of HbA assembly starting from isolated αH and βH subunits.  
 
Medical Relevance of AHSP 
The participation of AHSP in HbA biosynthesis prompted early 
speculation that AHSP dysregulation may play a causative role in certain 
diseases (443). The relationships between AHSP and various thalassemia 
syndromes have been of particular interest. Viprakasit et al. (481) investigated 
whether variations in the apparent clinical severity of HbE β thalassemia could 
be explained by the presence of mutant ahsp alleles among affected individuals. 
Several single nucleotide polymorphisms (SNPs) were identified, but none of 
them were found to correlate with the severity of the thalassemic phenotype 
(481). Other work has shown that both healthy and thalassemic individuals may 
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Figure 1-9. Proposed functional roles of AHSP 
Panel A depicts the different roles that AHSP occupies during αH chain biosynthesis. 
Panel B depicts a scheme which situates these events as part of the larger process of 
HbA biosynthesis. Colors, ribbon, and stick forms are the same as those utilized in 
Figure 1-8. Panel A was produced using the PyMol Molecular Graphics System and 
PDB entry 1Z8U (DeLano Scientific, Palo Alto, California, US)(471). Panel B was 
produced using ChemDraw Pro with significant assistance from John S. Olson. 
possess an uncommon missense mutation that results in AHSP with an 
isoleucine at position 75 instead of an asparagine (N75I)(470, 482, 483). This 
mutation does not occur at the AHSP:αH-chain interface, but initial work 
suggests that it may nonetheless be functionally important (470, 482, 483).  
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In another study, Lai et al. (484) have shown that ahsp mRNA levels in 
reticulocytes vary considerably in healthy individuals, and several sequence 
variants have been identified which affect ahsp transcription levels and may be 
linked to the phenotypic discordance observed in certain types of β thalassemia. 
Also, a variant in ahsp intron 1 has been associated with altered AHSP 
expression levels and occurs commonly in healthy individuals (483). 
Interestingly, certain ahsp alleles bearing SNPs that are thought to result in 
diminished AHSP expression have been linked to Heinz body-, drug-, and 
infection-induced hemolytic anemia (485). Thus, ahsp gene expression levels 
and function appear to be relevant in a variety of clinical contexts, and ongoing 
work in this area is likely to be informative. 
Marden and co-workers have suggested that AHSP:αH-chain interactions 
are impeded by a proline to serine mutation at position 119 of αH chains (P119S; 
Hb Groene Hart), which results in an α thalassemia phenotype (486). Another 
αH chain mutation, F117S (Hb Foggia), also results in a phenotype typical of α 
thalassemia (487). This mutation is predicted to disrupt favorable interactions 
with AHSP (445, 487), and several investigators have recently looked directly at 
these issues by evaluating a set of clinically relevant αH chain mutations which 
might exhibit impaired AHSP interactions: H103L (Bronovo), C104Y 
(Sallanches), C104S (Oegstgeest), T108N (Bleuland), L109R (Suan Dok), 
L109Q, F117S (Foggia), P119S (Groene Hart), P119L (Diamant), and L129P 
(Utrecht)(440). 
Vasseur et al. (440) co-expressed GST-tagged wild-type AHSP with the 
GST-tagged mutant αH chains listed above in E. coli and quantified expression 
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levels of these αH chain mutants. The detection of variable amounts of soluble 
αH chains demonstrates that the selected amino acid replacements may have 
significant effects on the stability of the AHSP:αH-chain interface (440). 
However, the mutations selected occur in a region of the αH chains that is part 
of the shared interface for binding to both AHSP and βH chains. Thus, these 
results are ambiguous, and it is unclear which disrupted interactions, AHSP:αH-
chain or αH1βH1, give rise to the observed phenotypes. Most recently, this group 
has reported the discovery and characterization of a novel AHSP mutant, V56G, 
which has been linked to thalassemia syndrome (488). 
In Chapters 3 through 6, the rate constants associated with AHSP 
binding to and dissociation from native ferric and ferrous human α subunits are 
reported, along with the binding and dissociation equilibrium constants. Also, 
several mutant AHSP proteins were used to better define the cis-trans peptidyl-
prolyl isomerization events that AHSP is known to undergo, and several 
naturally occurring human α subunit missense mutants were used to probe 
AHSP function. Additionally, several post-binding events regarding AHSP:α-
subunit interactions were investigated, such as autooxidation, heme uptake, 
hemin loss, effects on ligand binding, and secondary structure acquisition. 
Finally, AHSP was co-expressed with α and β subunits in transgenic E. coli as a 
way of probing the effects of AHSP on hemoglobin production. Collectively, 
these investigations were undertaken to better define AHSP function in vivo.  
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Chapter 2: Materials, Methods, Instruments 
Human AHSP Expression, Purification 
AHSP was obtained using the bacterial expression vector pGEX-2T that 
had the human ahsp gene inserted into its multiple cloning site (NCBI 
Accession NM_016633.2 for AHSP and U13850.1 for empty vector)(114). This 
empty vector was manufactured by GE Healthcare Bio-Sciences Corporation 
(Piscataway, New Jersey, US). This plasmid, which will be referred to as 
pGEX2T-AHSP, was provided by and constructed in the Laboratory of Mitchell 
J. Weiss at the University of Pennsylvania (443, 444). The coding regions were 
sequenced upon receipt using sequencing primers that were designed by the 
manufacturer and synthesized by Integrated DNA Technologies, Inc. 
(Coralville, Iowa, US) (5'-CCG GGA GCT GCA TGT GTC AGA GG-3' and 5'-GGG 
CTG GCA AGC CAC GTT TGG TG-3'). The human ahsp gene in this vector was 
not optimized for E. coli codon bias. Sequencing reactions for these and other 
reactions were performed by Lone Star Laboratories, Incorporated (Houston, 
Texas, US). Glycerol stocks of DH5α cells were prepared to maintain pGEX2T-
AHSP and other plasmids using the methods outlined in Sambrook et al. (489). 
The cells purchased from Invitrogen Corporation (Carlsbad, California, US). 
Unless otherwise noted, the molecular biology protocols set forth in Sambrook 
et al. (489) were used throughout this work. 
The pGEX2T-AHSP vector consists of ahsp that had been cloned 
downstream and in the correct reading frame of the S. japonicum glutathione 
S-transferase (gst) gene (NCBI Accession U13850.1, region 258..956)(114). The 
AHSP protein produced from this vector has GST protein appended to its N-
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terminus. The theoretical molecular masses of these proteins are 26,986.32 Da 
in the case of GST and 11,840.42 Da in the case of AHSP, giving GST-AHSP a 
total molecular mass of ~38,826.74 Da according to the ExPASy Proteomics 
Server and known protein sequences (http://expasy.org/tools/ pi_tool.html; 
NCBI Accession U13850.1 and NM_016633.2)(114). GST can be freed from 
AHSP using thrombin protease, although this leaves a gly-ser dipeptide 
appended to the N-terminus of the resulting AHSP protein due to the protease 
recognition site. This vector contains a pBR322 origin of replication, confers 
ampicillin resistance upon its host, and expresses GST-AHSP under the control 
of a tac promoter. It is approximately 5,200 base pairs in length with the ahsp 
insert. 
Several components of this work involved the use of recombinant AHSP 
mutants. These mutants were generated using the QuikChange II Site-Directed 
Mutagenesis Kit (Stratagene Corporation, La Jolla, California, US, later 
acquired by Agilent Technologies, Incorporated, Santa Clara, California, 
US)(490). AHSPP30A was generated using the following mutagenic primers 
(emboldened codons indicate the region of mutation): 5‘-CTG AAT CAG CAG 
GTC TTC AAT GAT GCG CTC GTC TCT GAA GAA GAC-3‘ and 5‘-GTC TTC TTC 
AGA GAC GAG CGC ATC ATT GAA GAC CTG CTG ATT CAG-3‘. AHSPP30W was 
generated using these primers: 5‘-GTC TTC TTC AGA GAC GAG CCA ATC ATT 
GAA GAC CTG CTG ATT CAG -3‘ and 5‘-CTG AAT CAG CAG GTC TTC AAT 
GAT TGG CTC GTC TCT GAA GAA GAC-3‘. AHSPD29R was generated using 
these primers: 5‘-AAT CAG CAG GTC TTC AAT CGT CCT CTC GTC TCT GAA 
GAA G-3‘ and 5‘- C TTC TTC AGA GAC GAG AGG ACG ATT GAA GAC CTG 
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CTG ATT-3‘. AHSPQ25K was generated using these primers: 5‘-C AGC GTT CTG 
CTG AAT CAG AAG GTC TTC AAT GAT CCT CTC-3‘ and 5‘-GAG AGG ATC 
ATT GAA GAC CTT CTG ATT CAG CAG AAC GCT G-3‘. Site-directed 
mutagenesis reactions were carried out in accordance with instructions 
provided by the manufacturer (490), and sequences were verified and glycerol 
stocks prepared using the methods described above. 
AHSP expression was performed in E. coli BL21 cells using protocols 
initially developed in the Laboratory of Mitchell J. Weiss. This protocol is 
summarized as follows. 
BL21 cells were purchased from Agilent Technologies, Incorporated 
(Santa Clara, California, US). Chemically competent BL21 cells were first 
transformed with pGEX2T-AHSP in accordance with vendor transformation 
guidelines (491). After transformation, cells were plated on Luria-Bertani (LB) 
agar plates with 100 µg/mL of ampicillin and incubated overnight at 37 OC. 
Following overnight incubation, a single colony was used to inoculate a 1 L 
Erlenmeyer flask containing 250 mL of sterile 2x YT medium containing 100 
µg/mL of ampicillin. This culture was grown at 37 OC with shaking at 225 
revolutions per minute (RPM) overnight before being evenly and aseptically 
distributed into six, 4 L Erlenmeyer flasks, each of which contained 1 L of sterile 
2X YT medium with 100 µg/mL of ampicillin. 
Cultures were grown at 37 OC at 225 RPM until the optical absorbance at 
600 nm reached 0.8 to 1.0, at which time the culture temperatures were 
dropped to 32 OC and were induced with 1.0 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) for 6 hours before harvesting by centrifugation at 
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10,000 x g for 40 minutes at 4 OC. The cells were resuspended in approximately 
200 mL of ice cold phosphate buffered saline (PBS) solution (140 mM NaCl, 3 
mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4 at 20 OC), and were 
disrupted using an Emulsiflex-C5 high pressure homogenizer (Avestin, Ottowa, 
Ontario, Canada). The lysate was then centrifuged to remove cell debris, and 
the supernatant was passed through a 0.2 µm filter (Fisher Scientific, 
Pittsburgh, Pennsylvania, US). 
The soluble GST-AHSP present in the supernatant was captured using 
approximately 50 mL of Glutathione Sepharose High Performance (HP) resin 
in accordance with manufacturer instructions (GE Healthcare Bio-Sciences 
Corporation, Piscataway, New Jersey, US). During this process, PBS was used 
as a binding and wash buffer, and 50 mM Tris-HCL with 10 mM reduced 
glutathione, pH 8.0 at 4 OC, was used as an elution buffer. This step of the 
purification was performed using either a gravity-fed column or one that was 
equipped with a Masterflex peristaltic pump (Cole Parmer, Vernon Hills, 
Illinois, US). Clarified lysate was applied to the column and washed until the 
optical absorbance of the flow-through in the middle ultraviolet (UV) range 
(200-300 nm) matched that of the binding and wash buffer. Then, elution of 
AHSP was followed by monitoring light absorbance at 280 nm of various 
fractions of the flow-through. 
Without concentrating or buffer exchanging the eluate, GST was cleaved 
from AHSP using 500 units of thrombin in an overnight incubation at room 
temperature with mild agitation. The thrombin was obtained from GE 
Healthcare Bio-Sciences Corporation (Piscataway, New Jersey, US), and 
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manufacturer literature defines one unit of thrombin as capable of digesting 
>90% of 100 µg of test fusion protein in 16 hours at 22 OC (492). Following 
digestion, the reduced glutathione, free GST, thrombin, and untagged AHSP 
were dialyzed exhaustively against PBS buffer at 4 OC to remove the reduced 
glutathione. Then, the solution was again passed through the Glutathione 
Sepharose HP resin to remove as much free GST and uncleaved GST-AHSP as 
possible. Lastly, thrombin, residual GST, residual GST-AHSP, and un-tagged 
AHSP were resolved by size exclusion chromatography using a preparative 
grade Superdex 75 prepacked column and an ÄKTA fast protein liquid 
chromatography (FPLC) system (GE Healthcare Bio-Sciences Corporation, 
Piscataway, New Jersey, US). A representative sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) gel of the various purification 
fractions are show in Figure 2-1.  
 
Figure 2-1. AHSP purification stages 
The materials used in the preparation of this SDS-PAGE gel were obtained from 
Invitrogen Corporation (Carlsbad, California, US). The numbers listed on the left side 
of the gel are molecular masses in kDa. This marker was Mark 12 Unstained Standard, 
and the gel was a pre-cast NuPAGE 4-12% bis-tris gel that was run in MES running 
buffer and stained with Coomassie stain. 
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All solutions and buffers were maintained at 4 OC throughout the 
purification. Approximately 6 L of bacterial culture yielded approximately 100 
mg of fusion protein. AHSP was remarkably stable throughout all purification 
steps, and protein was stored at -80 OC in PBS buffer.  
The experimentally determined molar extinction coefficients used to 
determine the concentrations of wild-type AHSP were 10,825 M-1 cm-1 at 280 
nm in 6 M guanidinium HCl, and 12,300 M-1 cm-1 at 280 nm in H2O (provided 
by David Gell at the University of Sydney, personal correspondence). The 
mutant AHSP protein molar extinction coefficients were calculated using the 
ExPASy Proteomics Server (http://expasy.org/tools/ protparam.html). This 
tool revealed that AHSPWT, AHSPP30A, AHSPD29R, and AHSPQ25K all are 
predicted to share the same extinction coefficient of 11,460 M-1 cm-1 at 280 nm 
in H2O. Since the value provided by David Gell was experimentally determined, 
it was used over the theoretical value for concentration determinations for wild-
type AHSP and these mutants. However, the presence of an extra tryptophan in 
AHSPP30W resulted in an increased theoretical molar extinction coefficient of 
16,960 M-1 cm-1 at 280 nm in H2O. This value was used in this work rather than 
an experimentally determined one. 
To clone the ahsp gene into pBAD33, the pGEM-T Vector System was 
utilized (Promega Corporation, Madison, Wisconsin, US). Additionally, the 
following primers were used: 5‘ TAT GGT ACC AGG AGG AAT TCA CCA TGG 
CTC TTC TTA AGG CC 3‘ and 5‘ GGC ATG CGA TAA GCT TCT AGG AGG AGG 
GCG GTG G 3‘. Co-transformations were accomplished using the Z-Competent 
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E. coli Transformation Kit that was purchased from Zymo Research 
Corporation (Irvine, California, US). 
 
Native Wild-Type Adult Human Hemoglobin Purification 
HbA was obtained from expired units of human blood or PRBCs that 
were purchased from the Gulf Coast Regional Blood Center (Houston, Texas, 
US). HbA was purified using established methods (493). Briefly, erythrocytes 
from PRBCs were washed several times with a solution of 0.9% NaCl and 
resuspended in an equal volume of cold, deionized water that had been 
saturated with CO prior to its use. The suspension was incubated at 4 OC 
overnight to induce osmotic lysis. The NaCl concentration of the solution was 
then increased to 3% (w/v), after which it was clarified by centrifugation at 
10,000 x g for 60 minutes at 4°C. The supernatant was then dialyzed 
exhaustively against 30 mM Na2HPO4 at 4 OC. Bound 2,3-bisphosphoglyceric 
acid (BPG) was removed from the HbA by buffer exchanging the solution into 
10 mM Tris-HCL, 100 mM NaCl, pH 8.0 using a Sephadex G-25 column. HbA 
was stored in liquid N2 in the CO-bound form in 100 mM sodium or potassium 
phosphate buffer, pH 7.4 at 4 OC, when it was not being used.  
To convert CO-bound HbA to O2-bound HbA, solutions of Hb were 
placed in a round bottom flask, which was rotated and partially submerged in 
an ice water bath while being exposed to a strong light source and pure O2 gas. 
Periodically the absorbance spectrum of the sample was monitored to follow the 
conversion to the O2-bound form. To deoxygenate the protein, a concentrated 
solution of O2-bound HbA was diluted into a buffer that had been thoroughly 
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bubbled with pure argon or nitrogen gas. Then, excess sodium dithionite (DT) 
was added to the solution and optical absorption spectroscopy was used to 
verify that the protein was completely deoxygenated. To oxidize the protein, 
equimolar amounts of potassium ferricyanide were added to CO- or O2-bound 
HbA or isolated subunits, and optical absorbance was again used to monitor the 
transition to the ferric state. Alternatively, vast excess amounts of potassium 
ferricyanide were added to a sample, after which it was incubated at 4 OC for 20 
to 30 minutes before using a Sephadex G-25 column to remove the excess 
potassium ferricyanide. Known molar extinction coefficients and optical 
absorbance maxima and minima in the visible and ultraviolet ranges were used 
to determine HbA, αH chain, and βH chain concentrations and ligand binding 
and oxidation state (494-496). 
 
Alpha, Beta Subunit Isolation 
HbA subunits were also isolated using previously developed methods 
which will be summarized here (194, 195, 497). CO-bound HbA was first buffer 
exchanged into 10 mM KH2PO4, 80 mM NaCl buffer at 4 OC. Then, the protein 
was concentrated to approximately 1.6 mM HbA on a per tetramer basis. In a 
separate solution, enough ρ-hydroxymercuribenzoate (PMB) was dissolved in 1 
mL of 0.1 N NaOH to give at least a six fold molar excess of PMB over HbA. For 
approximately 10 mL of a 1.6 mM HbA solution, this amounts to approximately 
35 mg of PMB. Then, small amounts of 1 M acetic acid were added to the PMB 
solution with vigorous agitation until the formation of a very small amount of 
white precipitate was observed. The entirety of this solution was then added to 
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the 10 mL HbA solution, and the pH of the resulting mixture was adjusted to 
6.2 using 1 M acetic acid. This solution was allowed to stand at 4 OC overnight 
in a stoppered Erlenmeyer flask whose headspace was filled with CO. This 
amount of PMB causes the HbA cysteines, which occur at the inter-subunit 
interfaces, to react with PMB and split the HbA into individual subunits.  
The next morning, the solution was passed through a gravity fed 
Sephadex G-25 column to exchange the solution into 10 mM potassium 
phosphate buffer, pH 8.0 at 4 OC. The resulting solution was then concentrated 
to a small volume (<15 mL) and applied to a diethylaminoethyl (DEAE) column 
that was previously equilibrated with the same buffer. The αH chains elute from 
this column under these buffer conditions, whereas the βH chains and 
tetrameric HbA are retained by the resin. HbA was subsequently eluted by 
transitioning the buffer to 20 mM potassium phosphate buffer, pH 7.5 at 4 OC, 
and then the βH chains were eluted from the resin by again transitioning to 100 
mM potassium phosphate, pH 7.0 at 4 OC. The HbA fraction was discarded, and 
the αH and βH chain fractions were then buffer exchanged into 20 mM 
potassium phosphate buffer, pH 7.4 at 4 OC. All these purification steps were 
performed at 4 OC using buffers that were saturated with CO prior to use in 
order to diminish heme iron oxidation. 
The αH and βH chains produced using this procedure have PMB reacted 
with their cysteine groups at the end of the protocol, and it was necessary to 
remove the PMB groups so that subunit re-assembly events could be studied in 
vitro. Removal was accomplished using a modified version of the method 
reported by Geraci et al. (195). Briefly, the isolated chains were incubated with a 
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10-fold molar excess of β-mercaptoethanol (BME) on ice for approximately 30 
minutes. Then, the solutions were buffer exchanged into 100 mM potassium 
phosphate buffer, pH 7.4 at 4 OC, using a gravity fed Sephadex G-25 column. 
Depending on the results of the assay described in the next paragraph, this 
procedure was repeated several times in order to ensure the complete removal 
of all PMB groups from the chains. 
To confirm the removal of the PMB groups, a Boyer titration was 
performed (498). This method involves titrating sub-stoichiometric amounts of 
PMB into dilute solutions of either αH or βH chains of a known concentration 
and monitoring optical absorbance spectral changes at 255 nm (498). Changes 
at this wavelength report on mercaptide bond formation between cysteines and 
PMB (498). Alpha chains have one cysteine and βH chains have two cysteines, 
and incrementally increasing the titer of PMB up until the point of equimolarity 
results in absorbance increases at 255 nm. Once cysteine:PMB equimolarity is 
reached, no further increases in absorbance are observed. After PMB removal 
was established using this method, the purities of the isolated αH and βH chains 
were verified by cellulose acetate electrophoresis (CAE). This method separates 
αH and βH chains on the basis of charge. Because isolated chains are 
approximately the same molecular mass, this method is more suitable than 
SDS-PAGE gel analysis. Figure 2-2 contains representative data for a Boyer 
titration and a CAE analysis. 
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Figure 2-2. Boyer titration, subunit purity determination 
Panel A, spectra of βH chains before and after Boyer titration. Panel B, 
absorbance changes at 255 nm plotted against PMB concentration. In 
Panel B, βH chain concentration was 12 µM, giving cysteine 
concentration of 24 µM. Panel C, CAE membrane. The slight HbA 
contamination in the αH chain sample indicated that re-purification 
was necessary. Materials, buffers and apparatus for the CAE membrane 
were obtained from Helena Laboratories, Incorporated (Beaumont, 
Texas, US). Proteins were stained with Ponceau S stain. Plots were 
generated using Microsoft Excel (Microsoft Corporation, Redmond, 
Washington, US). 
 
Heme Extraction from Isolated Subunits 
Preparation of αO and βO chains was done using the acid-acetone method 
that is described elsewhere (172, 173, 192, 499). Samples containing 5 mL of 1 
mM ferric chains were exhaustively dialyzed against cold water. Care was taken 
during this step to prevent rupture of the dialysis bags due to the large osmotic 
pressure differential between the initial contents of the dialysis bag and pure 
water. Although desalting columns were attempted, the total absence of salt 
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caused the protein to interact with the gel filtration resin, leading to appreciable 
band spreading during sample migration through the column. After all salts 
were removed, the ferric Hb solution was then added dropwise to a 200 mL 
volume of acetone containing 5 mM HCl which was previously been cooled to at 
least -20 OC using a dry ice-ethanol bath. Following the addition of the protein, 
hemin remained in solution while globin formed a white precipitate. The 
solution was then centrifuged at 5,000 RPM at -20 OC for 30 minutes using 
glass centrifuge tubes to collect the precipitate. The hemin-containing solution 
was then removed and the precipitate resuspended in a small volume of cold 
water. This solution was then dialyzed into 50 mM potassium phosphate buffer, 
pH 7.4 at 4 OC. Precipitation usually occurred at this stage, often to an 
appreciable extent, and these aggregates were removed prior to storage by brief 
centrifugation using an Eppendorf centrifuge (Hamburg, DE) at 4 OC. Both αO 
and βO chains are highly unstable at temperatures above 5 to 7 OC in most dilute 
aqueous buffers. Occasionally, the above steps needed to be repeated to remove 
residual hemin. 
 
Recombinant HbA and HbF Production, Mutagenesis 
Recombinant HbA and HbF were produced using an expression system 
developed by Shen (213, 216) and Hoffman (211). In this system, JM109 cells 
are transformed with an Hb-expression plasmid, either pHE2 for HbA or pHE9 
for HbF (pHE2 was provided by C. Ho and T-J. Shen, Carnegie Mellon 
University, Pittsburgh, Pennsylvania, US; and pHE9 was provided by K. Adachi, 
The Children‘s Hospital of Philadelphia, Philadelphia, Pennsylvania, US). These 
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plasmids are very similar to each other, and each contains a single globin 
expression cassette which bears codon-optimized sequences which encode α 
and β globin proteins for HbA expression, and α and γ globin proteins for HbF 
expression. Individual globins are expressed as separate polypeptides from a 
single transcript under the control of a tac promoter. These vectors confer 
ampicillin resistance upon their host. They also express methionine amino 
peptidase (MAP), which cleaves the N-terminal methionine residue from each 
globin chain to produce recombinant Hb that is ―essentially identical‖ to native 
Hb (213, 216).  
Several mutants were prepared using the same methods as described 
above for AHSP. Specifically, HbAαK99E was produced using the primers: 5‘- 
CCG GTT AAC TTC GAA CTG CTG TCT CAC TGC C-3‘ and 5‘- GGC AGT GAG 
ACA GCA GTT CGA AGT TAA CCG G-3‘. Also, HbFγV67M was produced using 
the primers: 5‘- GTC AAG GCA CAT GGC AAG AAG ATG CTG ACT TCC TTG 
GGA GAT GCC-3‘ and 5‘-GGC ATC TCC CAA GGA AGT CAG CAT CTT CTT 
GCC ATG TGC CTT GAC-3‘. 
Both HbA and HbF expression were performed by flask fermentation 
using a protocol that was provided to the Olson Laboratory by Nancy Ho from 
the Department of Biological Sciences at Carnegie Mellon University (personal 
correspondence between Jayashree Soman and Nancy Ho). According to this 
protocol, following the transformation of pHE2 or pHE9 into JM109 cells that 
were purchased from Agilent Technologies, Incorporated (Santa Clara, 
California, US), a single colony was used to inoculate a 5 mL pre-culture 
consisting of LB media with 100 µg/mL ampicillin. After approximately eight 
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hours of growth at 32 OC, 225 RPM, the entirety of this pre-culture was used to 
inoculate two, 1 L flasks, each containing 250 mL of sterile terrific broth (TB) 
media with 100 µg/mL ampicillin (2.5 mL of pre-culture per flask). These 
cultures were grown overnight at 32 OC at 225 RPM, and the next morning they 
were split aseptically into six, 4 L Erlenmeyer flasks, each of which contained 
500 mL of sterile TB media with 100 µg/mL ampicillin. For inoculation at this 
stage, 50 mL of culture were utilized per each 4 L flask, giving an initial optical 
absorbance at 600 nm of approximately 0.6-1.0 arbitrary absorbance units 
(a.u.). These cultures were grown under the same conditions for approximately 
6 hours post inoculation before protein expression was induced with 50 mg/mL 
IPTG. At the time of induction, the temperature was dropped to 32 OC, and 50 
mg/L hemin was added to the media. Harvesting by centrifugation at 10,000 x 
g for 45 minutes at 4 OC occurred approximately four hours post-induction. 
Purification of HbF and HbA was also performed using methods which 
were developed by others (500, 501). This method will be summarized briefly 
here. After harvesting, the cell pellet was resuspended in approximately 100 mL 
of 40 mM Tris-HCL, pH 8.6 at 4 OC, with 1 mM benzamidine, and then the cells 
were disrupted using an Emulsiflex-C5 high pressure homogenizer (Avestin, 
Ottowa, Ontario, Canada). The lysate was then placed in an Erlenmeyer flask, 
and the headspace of this flask was gassed with CO and stoppered. The flask 
was allowed to stand overnight at 30 OC with no agitation to facilitate 
contaminant precipitation. The next morning, the lysate was clarified by 
centrifugation at 10,000 x g for 40 minutes at 4 OC and passed through a 0.2 
µm filter (Fisher Scientific, Pittsburgh, Pennsylvania, US). This clarified lysate 
48 
was then applied to an immobilized metal ion affinity chelating (IMAC) column 
equipped with a Masterflex peristaltic pump (Cole Parmer, Vernon Hills, 
Illinois, US). The column had been packed with Chelating Sepharose HP media 
and was charged with zinc acetate and equilibrated in accordance with 
manufacturer instructions before use. All buffers were bubbled with CO prior to 
their use and this and subsequent steps of the purification were all performed at 
4 OC.  
During and following the application of the clarified lysate to the column, 
the flow rates utilized were consistently near the upper limits of those that were 
recommended by the manufacturer. The dark red protein bound to the resin, 
and the following wash steps were performed: (1) 3 column volumes of 20 mM 
Tris-HCL, 500 mM NaCl, pH 8.5 at 4 OC, (2) 2 column volumes of 200 mM 
Tris-HCL, pH 8.5 at 4 OC, and (3) 3 column volumes of 20 mM Tris-HCL, pH 
8.5 at 4 OC. Then, the HbA or HbF was eluted using 20 mM Tris-HCL, 15 mM 
EDTA, pH 8.5 at 4 OC. Each successive wash removed impurities which were 
discarded. 
Although the HbA and HbF was generally >90% pure following the 
completion of these steps, two more columns were routinely utilized to remove 
residual contaminants, a SOURCE 15Q and a SOURCE 15S column. These 
columns were successively used in accordance with the methods described by 
Hoffman et al. (211). 
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Mass Spectrometry 
Following wild-type and mutant AHSP purification, an AHSP SDS-PAGE 
gel band was cut out and sent for liquid chromatography-mass spectrometry 
analysis (LC-MS/MS) at ProTech, Inc. (Norristown, Pennsylvania, US). This 
technique, along with matrix-assisted laser desorption/ionization time of flight 
(MALDI-TOF) mass spectrometry experiments performed on campus, 
confirmed the identity of AHSP. Also, HbF, mutated HbF, αH and βH chain 
identity and purity was assayed by MALDI-TOF mass spectrometry as well. 
 
Instrumentation, Materials 
Manual mixing spectrophotometry was done using either a Cary 50Bio 
(Varian, Incorporated, Palo Alto, California, US) or a UV2401PC 
spectrophotometer (Shimadzu, Incorporated, Columbia, Maryland, US) using 
cuvettes purchased from Starna Cells (Atascadero, California, US). CD 
spectropolarimetry was measured in a Jasco J-810 spectropolarimeter. 
Stopped-flow spectrophotometry was done using either a modified Durrum 
Model D-110 (Palo Alto, California, US) or an Applied Photophysics PiStar CD 
and fluorescence stopped-flow spectrophotometer (Leatherhead, Surrey, UK). 
Glass syringes were used whenever possible in the stopped-flow experiments to 
prevent atmospheric gas contamination (Cadence Science, Lincoln, Rhode 
Island, US), and all buffers, salts, and media components used for these 
experiments were obtained from either Sigma-Aldrich (St. Louis, Missouri, US) 
or Fisher Scientific (Pittsburgh, Pennsylvania, US). During the fluorescence 
stopped-flow experiments, a 302 nm cutoff filter was utilized to monitor total 
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fluorescence upon excitation at 280 nm. Unless otherwise noted, the resins 
utilized in the purifications described above were obtained from GE Healthcare 
Bio-Sciences Corporation (Piscataway, New Jersey, US). 
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Chapter 3: AHSP Binding to and Dissociation from Human Alpha Chains  
 
Although two previously reported studies have examined the rates and 
equilibria of αH chain binding to and dissociation from AHSP (1, 488), neither 
of these studies were comprehensive in terms of detailed mechanisms. It is 
important to fully characterize these reactions because doing so will inform our 
understanding as to which pathways are the dominant routes for  HbA subunit 
assembly (Figure 1-9B). In the experiments presented in this chapter, various 
forms of αH chains were mixed with AHSP to measure bimolecular association 
rate constants, and AHSP:αH-chain complexes were mixed with excess βH 
chains to measure the rate constants for AHSP:αH-chain dissociation. 
 
AHSP, Alpha Chain Association  
Wild-type human AHSP exhibits intrinsic fluorescence in solution due to 
the presence of one tryptophan and four tyrosines, several of which are located 
at the AHSP:αH-chain binding interface (502). Although individual αH and βH 
chains contain numerous aromatic residues (48 per HbA tetramer, with 1.5 
tryptophans per subunit), neither of these subunits exhibit strong intrinsic 
fluorescence due to highly efficient energy transfer between their aromatic 
residues and the heme prosthetic groups (fluorescence quenching has been 
estimated at >99% for αH chains and ~98% for βH chains)(503, 504). When 
AHSP is bound to an αH chain, this energy transfer quenches intrinsic AHSP 
fluorescence (502). The key residue is AHSP Trp44 (502), which occurs in helix 
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2, is solvent-exposed in unbound AHSP, but becomes buried when this protein 
binds to an αH chain (Figures 1-6, 1-7, and 1-8)(445).  
Figure 3-1 depicts several experiments which expand on the early work 
of Baudin-Creuza et al. (502) on intrinsic AHSP fluorescence. Figures 3-1A and 
3-1B show that upon excitation with light at 280 nm, AHSP fluoresces in 
solution, whereas αH and βH chains do not. These panels also show that adding 
an equimolar amount of αH chains to a solution of AHSP greatly diminishes the 
apparent intrinsic fluorescence of AHSP (Panel A). To a lesser extent, βH chains 
exert the same effect (Panel B), which in this case is probably not due to direct 
binding but to an inner filter effect as a result of the βH chains absorbing some 
of the exciting light. Panel C shows the fluorescence intensity of AHSP as it is 
titrated into the following solutions: (1) buffer alone, (2) buffer containing 15 
µM αH chains, and (3) buffer containing 15 µM βH chains. As AHSP is titrated 
into solutions of αH chains, its intrinsic fluorescence signal is silenced up to the 
point of AHSP and αH chain equimolarity. Then, further increases in AHSP 
concentration result in a linear increase in fluorescence emission intensity. By 
contrast, this initial fluorescence signal silencing is completely absent in the 
titration involving βH chains, and there is a linear signal increase throughout 
the titration as AHSP is added to the βH chain solution. 
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Figure 3-1. Intrinsic fluorescence emission of AHSP, αH chains, βH chains 
The buffer utilized for these experiments was 50 mM potassium phosphate, pH 7.0 at 
21 OC, which had been saturated with CO prior to use. For Panels A-C, the entrance and 
exit slits on the instrument were both set to 5 nm, and each scan was recorded over the 
course of less than one minute to avoid photobleaching. A Cary Eclipse scanning 
fluorescence spectrophotometer was used to collect these data using default settings 
unless otherwise noted (Agilent Technologies Inc., Santa Clara, California, US). Panel 
C plots emission intensity maxima at 350 nm and not total integrated values. Panel D 
documents the following reactions: (1) 250 nM AHSP + 250 nM βH chains, (2) 250 nM 
AHSP + buffer, (3) 250 nM AHSP with 250 nM αH chains + buffer, (4) 250 nM αH 
chains + 250 nM βH chains, (5) 250 nM αH chains + buffer, (6) 250 nM βH chains + 
buffer, and (7) buffer + buffer. The fluorescence increase observed in trace (3) is due to 
a small amount of dissociation of the AHSP:αH-chain complex following rapid dilution. 
Excitation for all experiments occurred at 280 nm. Concentrations listed here are post-
mixing values. For stopped-flow experiments, instrument slits were set to 5 nm, 
entrance and exit, and 1000 to 3000 data points were collected during symmetric 
mixing mode using a total shot volume of 150 µL. Plots were generated using Microsoft 
Excel and PowerPoint (Microsoft Corporation, Redmond, Washington, US). 
 
 
Baudin-Creuza et al. (2004) were the first investigators to report that 
fluorescence quenching during co-incubation of AHSP with αH chains is due to 
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the formation of a complex between the two proteins (502). They proposed a 
simple bimolecular binding mechanism 
 
AHSP* + αH ChainØ  AHSP:αH-ChainØ                 (Scheme 3-1) 
 
where (*) indicates fluorescence emission and (Ø) indicates the absence of a 
fluorescence signal.  
Fluorescence quenching is a useful method of studying protein-protein 
binding (505), particularly when one of the partners is a heme protein. For 
example, the binding of haptoglobin to αH1βH1 dimers results in a strong 
quenching of intrinsic haptoglobin fluorescence (506, 507). Also, fluorescence 
quenching has been shown to report on the binding of a fluorescent 2,3-
bisphosphoglyceric acid (BPG) analog to HbA (506, 507). Based on how heme 
groups quench fluorescence emissions (503), it seems clear that the loss of 
AHSP fluorescence signal observed in Figure 3-1A corresponds to a binding 
event. 
This idea is confirmed by the data in Panel C, which show that the AHSP 
fluorescence signal loss caused by αH chains only appears to occur when AHSP 
is present in equal or sub-stoichiometric amounts. Because AHSP and αH 
chains associate with each other in a one-to-one stoichiometry (443, 444), the 
signal increases observed when AHSP is in excess are likely due to the 
fluorescence of free, unbound AHSP. 
Based on comparisons of just Panels A and B of Figure 3-1, it is plausible 
that βH chains could also bind to AHSP. The lack of complete fluorescence 
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signal silencing in Panel B could mean that βH chains might have a lower 
affinity for AHSP, or that AHSP:βH-chain complexes are capable of greater 
intrinsic fluorescence than AHSP:αH-chain complexes. However, previous 
electrophoresis and gel filtration studies have consistently indicated that βH 
chains do not bind to AHSP (443, 444), and the titration data in Panel C 
support these studies.  
The cause of the apparent loss in fluorescence signal in Figure 3-1B is 
due to the absorbance of incident excitation light by βH chains (an inner filter 
effect). This conclusion is supported by the slopes of the lines in Panel C. The 
titration of free AHSP into solution by itself results in larger fluorescence 
signals than the titration of AHSP into the solution of βH chains. The linear 
nature of these fluorescence increases suggest that the βH chains do not interact 
with AHSP, but rather mask AHSP intrinsic fluorescence by absorbing incident 
light. If these two proteins were interacting, the initial part of the titration curve 
involving βH chains would be expected to exhibit no fluorescence or at least a 
smaller slope, as was observed with the titration involving αH chains. Thus, 
these fluorescence data support previous data (443, 444) which suggest that βH 
chains and AHSP are non-interacting species. 
Figure 3-1D shows the results of several preliminary fluorescence 
emission stopped-flow mixing reactions which were undertaken to determine 
rates of αH chain binding to AHSP. Equal volumes of AHSP and αH chains, βH 
chains, or solvent were mixed together rapidly and the total fluorescence 
emission signal of the mixture was recorded as a function of time. Multiple 
controls were examined to confirm that AHSP, αH chains, and βH chains do not 
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denature, aggregate, precipitate, oxidize, lose their prosthetic groups, 
photobleach, and/or otherwise react in a way which gives rise to fluorescence 
signal changes that could be misinterpreted as binding events following their 
rapid dilution in solvent. These dilution controls were essential to provide 
evidence that the observed fluorescence changes recorded on mixing AHSP 
with αH chains are due to binding and not denaturation and light scattering. 
The data in Figure 3-1D, are consistent with the fluorescence properties 
that are shown in Panels A-C of this figure. They show using rapid mixing 
instrumentation that αH and βH chains do not exhibit intrinsic fluorescence in 
solution, either following dilution or when mixed together. They also show that 
AHSP stably fluoresces in solution following rapid dilution, and that mixing 
various combinations of AHSP and βH chains does not result in detectible 
fluorescence changes on millisecond to second time scales. The only exception 
is the reaction of the AHSP:αH-chain complexes with buffer (Figure 3-1D, 
reaction 3), which shows an intermediate fluorescence signal and a small 
increase in fluorescence in the 2 to 4 seconds following mixing. This small 
increase reflects a small amount of αH chain dissociation from AHSP due to 
dilution of the complex. 
In contrast to these control reactions, a large quenching of the AHSP 
fluorescence signal is observed on time scales of less than 100 seconds when αH 
chains are mixed with AHSP. As shown in Figures 3-2A and 3-2B, the observed 
traces for the reaction of αH chains with AHSP are biphasic. The large fast phase 
shows a rate which is linearly dependent on αH chain concentration, and the 
small slow phase shows a rate which is concentration-independent and equal to 
57 
approximately 0.04 ± 0.01 s-1. In addition, the slow phase is not observed when 
the concentrations of αH chains are less than that of AHSP. 
 
Figure 3-2. AHSP association with αH chains 
The buffer utilized in this stopped-flow experiment was 50 mM potassium phosphate, 
pH 7.0 at 21 OC, which had been saturated with CO prior to use. Data were collected 
using the same instrument and configuration as in Figure 3-1D. The post-mixing AHSP 
concentration was fixed at 250 nM, with the concentration of αH chains being varied 
with post-mixing values listed in the right margins of each panel in units of nM. Plots 
were generated using Microsoft Excel and PowerPoint (Microsoft Corporation, 
Redmond, Washington, US). 
 
There are at least two plausible mechanistic explanations for the two 
phases observed when αH chains are mixed with wild-type AHSP. First, the fast 
phase could correspond to AHSP:αH-chain complex formation, followed by a 
slow phase that is due to structural rearrangements within AHSP and/or the αH 
chains. For example, alterations which affect the orientation and local 
environment of the AHSP Trp44 side chain, or its distance from the heme 
group, could cause slow additional fluorescence quenching following the large 
initial decrease in fluorescence due to bimolecular binding. A second possibility 
is that one of the proteins exists in two sub-populations, a fast-reacting 
population and a slow-reacting population. If each of the two populations bind 
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at different rates, their sequential depletion would give rise to biphasic 
fluorescence quenching.  
Most of the evidence argues against the first model. Although AHSP 
binding has been shown to induce structural rearrangements in oxygenated αH 
chains after binding, including those that are related to autooxidation and 
hemichrome formation (442, 445, 471, 473, 508), these rearrangements take 
hours at 20 OC to complete (see Chapter 4) and not seconds as depicted in 
Figures 3-2A and 3-2B. In addition, the experiments in Figure 3-2 used CO-
bound αH chains, which do not readily autooxidize or undergo heme pocket 
rearrangements. These experiments were also conducted at αH chain 
concentrations that were more than 100-fold lower than the dissociation 
equilibrium constant for αH chain self-dimerization. Thus, the slow phase 
cannot be attributed to a rate-limiting αH2 dimer dissociation event. Similarly, 
AHSP has been shown to remain monomeric in solution at much higher 
concentrations than the ones utilized in these experiments (444). 
The observed slow phases are only present when AHSP is mixed with 
equimolar or excess αH chains (Figure 3-2B). This kinetic pattern suggests that 
it is AHSP which exists in populations of fast- and slow-reacting species. If αH 
chain concentrations are lower than those of AHSP, the fast-binding population 
of AHSP is preferentially depleted before any slow-binding AHSP is able to 
react. Under these conditions, no second phase is observed because the slow-
binding population of AHSP has no free αH chain binding partners with which 
to interact. In contrast, when equimolar or excess αH chains are mixed with 
limiting AHSP, all of the free AHSP reacts, including the slow-reacting 
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population which gives rise to a second fluorescence quenching phase. If αH 
chains existed in fast- and slow-reacting populations, the opposite pattern 
would be predicted (that is, two phases would be observed when AHSP is 
present is in excess, with the abrogation of one phase when AHSP is limiting). 
Similarly, if the slow phase were being caused by structural rearrangements, 
this phase would also be predicted to occur with excess AHSP, although its rate 
might be affected. Thus, the two-conformation model for wild-type AHSP is 
consistent with the observed kinetic data.  
Further analysis of the kinetic titration shown in Figures 3-2A and 3-2B 
suggests that the fast phase corresponds to a simple bimolecular association 
reaction (Scheme 3-1). The association rate constant for AHSP binding (k‘AHSP) 
in this model can be obtained by plotting the observed rate constants for the 
fast phases versus the free αH chain concentration under pseudo first-order 
conditions where αH chains are in excess (Figure 3-3). Fitting data from four 
experiments gives an apparent association rate constant for AHSP binding of 
8.5 ± 2.1 μM-1s-1.  This is approximately 17-fold greater than the association rate 
constant for αH chain binding to βH chains, which occurs at a rate of 
approximately 0.5 μM-1s-1, irrespective of the ligand bound (See Figure 1-5)(198, 
201). 
As discussed in Chapter 1, wild-type AHSP is known to exhibit cis and 
trans conformations about the Asp29-Pro30 peptide bond. The binding of αH  
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Figure 3-3. AHSP, αH chain association rates 
unders pseudo-first order conditions 
Buffer conditions and experimental configuration are 
the same as those in Figure 3-2. Concentrations are 
listed as post-mixing values. Observed traces were fit to 
a single exponential equation, and the observed rate 
constants were plotted against αH chain concentration. 
The line represents a linear fit whose slope equals k‘AHSP. 
Figure generated using Microsoft Excel and PowerPoint 
(Microsoft Corporation, Redmond, Washington, US). 
 
chains quenches this conformational heterogeneity, and the initial work of 
Santiveri et al. (470) and Feng et al. (445) suggested that AHSP occupies the 
trans conformer upon binding. Santiveri et al. (470) estimated that the 
populations of cis and trans AHSP in the unbound form are roughly equal at 
room temperature, and their NMR chemical shift data indicate that the two 
species interconvert slowly in solution, with the interconversion occurring with 
a lifetime of ≥0.1 seconds (470).  
These initial NMR data and the time courses in Figure 3-2 suggested that 
the observed fast phase corresponds to the formation of (trans)AHSP:αH-chain 
complexes which occurs in less than a few seconds following mixing. The 
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observed slow phase would then correspond to a rate-limiting conversion of 
(cis)AHSP to (trans)AHSP, which then rapidly binds to free αH chains to form 
the final (trans)AHSP:αH-chain complex. This mechanism is depicted in Figure 
3-4.  
 
 
Figure 3-4. Mechanism of AHSP, αH chain association reaction 
Colors, ribbons, and stick forms are the same as those used in Figure 1-8, 
except (cis)AHSP is depicted in purple in this figure. Figure generated 
using Microsoft PowerPoint (Microsoft Corporation, Redmond, 
Washington, US) and the PyMol Molecular Graphics System and PDB 
entry 1Z8u (DeLano Scientific, Palo Alto, California, US)(471). 
 
 
More recent work by Gell et al. (508), however, suggests an alternate 
model. Their NMR and X-ray crystallographic data indicate that AHSP 
exclusively occupies the cis conformation in bound AHSP:αH-chain complexes. 
If true, then αH chain binding to (cis)AHSP is rapid and followed by a rate-
limiting interconversion of (trans)AHSP to (cis)AHSP before the remaining 
AHSP binds. Although this model contradicts the conclusions of Santiveri et al. 
(470), data from both research groups are consistent in indicating that only one 
peptidyl-prolyl conformation of AHSP exists in bound AHSP:αH-chain 
62 
complexes (470, 508). The data presented here indicate the presence of both 
proline isomers, although it is unclear which one is the fast-reacting species. 
Based on the relative amplitudes of each kinetic phase, it appears that 
20-30% of AHSP occupies one Pro30 peptidyl-prolyl conformation while 70-
80% occupies another at equilibrium (50 mM potassium phosphate buffer, pH 
7.3 at 20 OC). Although this estimate differs from the 50/50 mixture that 
Santiveri et al. (470) reported, it is consistent with other studies which show 
that at equilibrium, 60-90% of model oligopeptides occupy the trans peptidyl-
prolyl conformation and 10-40% the cis conformation (509). Additionally, the 
observed rate of the slow phase (0.04 ± 0.01 s-1) in Figure 3-2 is consistent both 
with the rate assignment of Santiveri et al. (470) and with other studies which 
show that cis/trans interconversion occurs spontaneously with time constants 
of 10 to 100 seconds at 25 OC (509). Also, the observations that the rate of the 
slow phase is (1) concentration-independent and (2) completely eliminated 
when αH chains are limiting are also supportive of a model involving AHSP 
binding that is rate-limited by cis/trans conformational interconversion. 
Several peptidyl-prolyl isomerases (PPIases) were obtained to further 
investigate these ideas. Based on personal correspondence with Christopher M. 
Dobson (University of Cambridge, Cambridge, UK), Hiram F. Gilbert (Baylor 
College of Medicine, Houston, Texas, US), and Franz X. Schmid (Universität 
Bayreuth, Bayreuth, Bavaria, DE), it was hypothesized that adding a PPIase to 
the solutions of AHSP prior to mixing them with αH chains might alter the rate, 
amplitude, and/or presence of the observed slow phase. If this were the case, 
this phase could be more directly attributed to AHSP cis-trans peptidyl-prolyl 
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isomerization. Human recombinant Cyclophilin-A and FK506 Binding Protein 
4 were selected for this purpose and obtained from Prospec Protein Specialists 
(East Brunswick, New Jersey, US). When AHSP was pre-incubated with either 
of the enzymes and then mixed with αH chains there was no change in the rate 
or amplitude of the slow phase. Most likely, the active sites of these PPIases 
have regio- and stereo-specificities that preclude interaction with Pro30 in the 
folded loop between helices 1 and 2 of AHSP. 
Another approach was to mutate the proline at position 30 in AHSP to 
an alanine residue (AHSPP30A). This mutation was previously shown by NMR 
spectroscopy to quench AHSP conformational heterogeneity in favor of the 
conformation observed for the trans Pro30 form (445, 470). The proline at 
position 30 was also mutated to a tryptophan (AHSPP30W), because this 
mutation was expected to have the same effect while conferring greater intrinsic 
fluorescence due to the presence of an extra tryptophan. Additionally, 
AHSPP30W was reported to have a different affinity for αH chains than wild-type 
AHSP (personal communications, Mitchell J. Weiss, University of 
Pennsylvania, Philadelphia, Pennsylvania, US).  
In stopped-flow experiments in which αH chains were mixed with these 
mutants, no slow phases were observed at any αH chain concentration 
examined. Representative kinetic traces are shown in Figure 3-5, and in these 
experiments the concentration of αH chains was increased to 8000 nM to look 
for slow phases. 
64 
 
Figure 3-5. Mutant AHSP association with αH chains 
The buffer utilized in this stopped-flow experiment was 100 mM potassium phosphate, 
pH 7.3 at 21 OC, which had been saturated with CO prior to use. Data were collected 
using the same instrument and configuration as in Figure 3-1, Panel D. The post-
mixing AHSP concentration was fixed at 250 nM, with the concentration of αH chains 
being varied with post-mixing values listed in the right margin of each panel in units of 
nM. Plots were generated using Microsoft Excel and PowerPoint (Microsoft 
Corporation, Redmond, Washington, US). 
 
As these data show, the concentration of αH chains affects not only the 
observed rates of the reactions, but also the apparent intensity of the 
fluorescence signal changes of each kinetic trace. For example, there is a clear 
upward shifting of the fluorescence traces observed in Figure 3-5 at αH chain 
concentrations higher than 500 nM. This same effect was observed in the 
experiments mixing wild-type AHSP with αH chains (not shown) and is a result 
of significant absorbance of both excitation and emitted  light by the αH chains. 
In addition, at higher αH chain concentrations, significant light scattering 
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occurs due to small amounts of denatured protein which increases the 
background fluorescence of each affected trace. Consistent with this 
explanation, the traces in Figure 3-1D show that mixing 250 nM αH chains with 
250 nM βH chains results in a larger apparent fluorescence signal than mixing 
either subunit with buffer alone (compare traces 4 through 7). Similar 
phenomena have previously been documented in other studies of hemoglobin 
solutions (510, 511), and these issues complicate the appearance of the time 
courses at high αH chain concentrations but not the kinetic analyses. Note that 
no slow phases are observed with these mutants despite the changes in 
intensities of the absolute fluorescence signals (Figure 3-5B and 3-5D). 
The time courses for the reactions involving AHSPP30A and AHSPP30W are 
all monophasic, with concentration dependences similar to the wild-type AHSP 
mixing reactions. The bimolecular rates of complex formation were calculated 
using the same method that was used for wild-type AHSP association with αH 
chains (Figure 3-3), and the association rate constants for AHSPP30A and 
AHSPP30W are 7.0 µM-1s-1 and 10.4 µM-1s-1, respectively, and nearly identical to 
that for wild-type AHSP. The plots of the observed rate constants versus αH 
chain concentration under pseudo first-order conditions where αH chains are in 
excess are shown in Figure 3-6. 
These data confirm that AHSP binding to αH chains is a rapid reaction 
that can be followed by fluorescence quenching. Additionally, they are 
consistent with a two-conformation model of AHSP structure. 
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Figure 3-6. Rate constants for mutant AHSP, αH 
chain association 
Buffer conditions and experimental configuration are 
the same as those in Figure 3-2. Concentrations are 
listed as post-mixing values. Observed traces were fit to 
a single exponential equation, and the observed rate 
constants were plotted against αH chain concentration. 
The line represents a linear fit whose slope equals k‘AHSP. 
Figure generated using Microsoft Excel and PowerPoint 
(Microsoft Corporation, Redmond, Washington, US). 
 
AHSP, Alpha Chain Dissociation 
It has been shown by size exclusion gel filtration chromatography and 
electrophoretic mobility shift assays that βH chains are capable of competitively 
displacing αH chains from AHSP:αH-chain complexes to form intact HbA (443, 
444, 471). Formation of HbA occurs because: (1) αH chains have a much higher  
affinity for βH chains than they do for AHSP (197, 201, 202, 205, 444), and (2) 
αH chains cannot simultaneously bind to AHSP and βH chains because both of 
these interactions involve the same set of αH chain helices at the complex 
interfaces (445, 471, 502). This displacement mechanism is depicted in Figure 
3-7. 
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Figure 3-7. AHSP, βH chain competition for free αH chains 
Equilibrium constants were measured using comparable buffer conditions (pH ~7 at 
~22 OC, buffered by 50 to 150 mM phosphate buffer). Colors, ribbons, and stick forms 
are the same as those used in Figures 1-1 and 1-9. Figure generated using the PyMol 
Molecular Graphics System and PDB entries 1Z8u and 1GZX (DeLano Scientific, Palo 
Alto, California, US)(196, 201-203, 205, 444, 471, 472). 
 
The only species in Figure 3-7 which exhibits strong intrinsic 
fluorescence in solution is AHSP that is not complexed with αH chains (502). 
Consequently, when AHSP:αH-chain complexes are mixed with βH chains, the 
displacement of αH chains from AHSP by βH chains results in an increase in 
fluorescence emission as free AHSP is generated (502). The rate at which this 
process occurs can be studied using the same fluorescence emission stopped-
flow device that was used to measure bimolecular binding. Preliminary studies 
using this approach have been reported by Brillet et al. (488) and Mollan et al. 
(1). 
At high AHSP and βH chain concentrations, the amount of free αH chains 
is small and in a steady-state during the displacement reaction. Under these 
conditions, the rate of the displacement reaction is given by: 
                           
(     )(    )[ 
       ]
(    )[ 
       ] (      )[    ]
                        (Equation 3-1) 
where kAHSP is the rate constant for dissociation of the AHSP:αH-chain complex, 
k‘AHSP is the association rate constant for AHSP:αH-chain complex formation, 
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and k‘αβ is the association rate constant for αH1βH1 dimer formation (1, 512, 513). 
By conducting displacement reactions at varied concentrations of βH chains and 
measuring the robs values for these reactions, Equation 3-1 can be used to obtain 
values for kAHSP and the ratio of k‘AHSP to k‘αβ (1). Expressions of this general 
form have previously been used to study the rates of ligand replacement for 
HbA and myoglobin (Mb)(512, 513). 
Representative traces for a set of displacement reactions are shown in 
Figure 3-8. As this figure shows, mixing βH chains with AHSP:αH-chain 
complexes results in an increase in the fluorescence emission of the resulting 
solution. The magnitudes of the fluorescence changes for these reactions are 
consistent with the AHSP displacement mechanism that is depicted in Figure 3-
7, and the observed time courses are monophasic at these concentrations. 
 
Figure 3-8. Displacement reaction 
concentration dependence 
Data were collected using 50 mM potassium phosphate 
buffer, pH 7.3 at 22 OC. The instrumental configuration 
was the same as in Figure 3-1D. Plots were generated 
using Microsoft Excel and PowerPoint (Microsoft 
Corporation, Redmond, Washington, US). 
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Because high concentrations of AHSP result in strong background 
fluorescence, these studies require the mixing of low concentrations of 
AHSP:αH-chain complexes with five-fold or greater concentrations of βH chains. 
This departure from pseudo-first-order conditions results in a varying 
concentration of free AHSP throughout the course of the reactions. In the 
analyses, the concentrations of free AHSP were fixed to 50% of their post-
mixing start values (125 nM). Additionally, because βH chains readily self-
associate to form homotetramers in solution, an upper limit of 8.0 µM βH 
chains (post-mixing value) was used to prevent the appearance of a slow phase 
due to βH4 tetramer dissociation (201).  
As Figure 3-9A shows, the displacement reaction involving AHSPP30W is 
dramatically slower than the reactions involving wild-type AHSP and AHSPP30A. 
Figure 3-9B shows the experimentally measured rates of replacement for these  
 
Figure 3-9. Wild-type and mutant AHSP, αH chain displacement reactions 
Panel A, plots of the displacement reactions for wild-type AHSP, AHSPP30A, and 
AHSPP30W. Panel B, theoretical replacement reaction curves plotted along with 
measured replacement rates for each protein. The data were collected using the same 
instrumental configuration as described in Figure 3-1D. Plots were constructed using 
Microsoft Excel and Microsoft PowerPoint (Microsoft Corporation, Redmond, 
Washington, US). 
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three proteins at varying concentrations of βH chains, as well as fitted 
replacement reaction rate curves generated using Equation 3-1. 
To obtain values for kAHSP and k‘αβ, k‘AHSP was fixed to the values 
determined from the bimolecular association reactions described in the 
preceding section. The values which give the best fits to Equation 3-1 are shown 
in Table 3-1. These values were then used to estimate the equilibrium 
dissociation constants for AHSP:αH-chain complex dissociation for all three 
AHSP proteins, which are also listed in this figure.  
 
 
Table 3-1. Kinetic parameters for wild-type and mutant AHSP, αH chain 
dissociation 
The data used in these calculations were collected using the same instrumental 
configuration as described in Figure 3-1D. Rate constants were calculated by fitting robs 
values from experiments like the one depicted in Figure 3-8 to Equation 3-1. The 
reactions involving AHSPP30A and AHSPP30W were repeated twice, and the numbers 
presented here constitute the average of the two calculated values. The reaction 
involving wild-type AHSP was repeated three times, and the numbers reported in the 
table are the mean values plus or minus (±) the standard deviation of the mean. The 
equilibrium dissociation constant was calculated by dividing kAHSP by k‘AHSP. 
Calculations were done using Microsoft Excel and the table was constructed using 
Microsoft PowerPoint (Microsoft Corporation, Redmond, Washington, US). 
 
The fitted values for k‘αβ roughly agree with those which were reported 
by McGovern et al. (201) and Kawamura and Nakamura (198)(0.5 µM-1s-1 and 
0.75 µM-1s-1, respectively). Also, the fitted values for k‘AHSP and kAHSP for wild-
type AHSP are similar to those that were independently determined by Brillet et 
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al. (488)(20 µM-1s-1 and 0.5 s-1 at 37 OC, respectively). Together, these data 
suggest a ~5-fold lower dissociation equilibrium constant for AHSP:αH-chain 
complexes than previous reports indicated (Gell et al. (444) reported a KD of 
100 nM at 20 OC).  
Two key results from this work are that: (1) the mutation of proline 30 to 
alanine in AHSP abolishes the slow association phase but with αH chain kinetic 
parameters that are equivalent to those of the rapidly-reacting conformer of 
wild-type AHSP, and (2) the Pro30Trp mutation causes a >25-fold increase in 
affinity for αH chains due to a >20-fold decrease in the AHSP:αH-chain 
dissociation rate constant. This increase in affinity for AHSPP30W was recently 
confirmed by Gell et al. (508), who reported a dissociation equilibrium constant 
for this protein of 7.7 ± 2.3 nM at 20 OC. Gell et al. (508) have also recently 
reported an affinity constant for AHSPP30A binding which is similar to the value 
determined in this work (33.0 ± 3.0 nM at 20 OC). 
 
AHSP Affinity for (O2), (CO), (met)Alpha Chains 
Feng et al. (445, 471) showed that AHSP binding induces structural 
rearrangements in αH chains, particularly in the area of the heme or hemin 
binding pocket. Because these alterations have been shown to affect αH chain 
oxidation chemistry and O2 binding (471, 473), it was hypothesized that the 
affinity of AHSP might be nonequivalent for αH chains with different oxidation 
states or bound ligands. 
To investigate this hypothesis, AHSP and αH chain association and 
dissociation reactions were studied using αH chains that were liganded with O2 
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and CO, as well as αH chains that had been oxidized to the ferric state using 
potassium ferricyanide ((met)αH chains). Using the previously described 
methods, bimolecular association reactions were measured to determine k‘AHSP. 
Once obtained, displacement reactions using (CO)βH chains were performed to 
obtain values for kAHSP and k‘αβ. The plots that were used to obtain k‘AHSP are 
shown in Figure 3-10A, and the theoretical replacement reaction rate curves are 
shown in Figure 3-10B. As was done in previous calculations, the values for 
k‘AHSP that had been determined from the bimolecular association reactions 
were fixed for determinations of kAHSP and k‘αβ.  
 
Figure 3-10. Kinetics of AHSP binding to and dissociation from (O2)-, (CO)-
, and (met)-αH-chains 
Panel A, plot depicting the rates of bimolecular association. Panel B, theoretical 
replacement reaction curves plotted along with measured replacement rates for each 
sample set. Plots were constructed using Microsoft Excel and Microsoft PowerPoint 
(Microsoft Corporation, Redmond, Washington, US). 
 
The rate constants obtained from these studies are set forth in Table 3-2. 
As these data indicate, there is a dramatic difference between the rates of 
displacement of (met)αH chains as compared to the reduced liganded 
complexes. Because the values for k‘AHSP are approximately equivalent for all 
three types of αH chains, this result indicates that AHSP has a much higher 
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affinity for (met)αH chains than it does for the other forms. There are several 
functional implications relating this finding. 
 
Table 3-2. Kinetic parameters for AHSP binding to and dissociation from 
(O2), (CO), and (met)-αH chains 
The data used in these calculations were collected using the same experimental 
conditions as was described in Figure 3-9. The experiments involving (O2)- and (met)-
αH-chains were not done in duplicate, though various methods of oxidizing AHSP:αH-
chains complexes were used to investigate and confirm the apparent slow rate of 
(met)αH-chain dissociation. The equilibrium dissociation constant was calculated by 
dividing kAHSP by k‘AHSP. The reactions involving (met)αH-chains are preliminary, 
though they have been reproduced in a series of slightly different assays. Calculations 
were done using Microsoft Excel and the table was constructed using Microsoft 
PowerPoint (Microsoft Corporation, Redmond, Washington, US). 
 
Isolated subunits and HbA in the met or ferric oxidation state are known 
to be less stable than their ferrous counterparts. One reason is that hemin loss 
is normally much faster from ferric heme proteins than from the reduced forms 
(153-157, 159, 170, 514, 515), resulting in apoprotein that rapidly denatures, 
aggregates, and precipitates (171-173). In vitro studies have shown that 
oxidation to the ferric state occurs spontaneously in the presence of O2 
(autooxidation)(41, 90, 516-523), but erythrocytes possess reductases which 
rapidly re-reduce these proteins to their more stable ferrous states in vivo (66, 
524, 525). Because AHSP has been shown to stabilize αH chains following 
binding (442, 443, 445, 469, 469, 471, 473, 526), the finding that AHSP binds to 
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(met)αH chains with a higher affinity than the other forms of αH chains suggests 
that it preferentially stabilizes subunits which are more in need of stabilization. 
Additionally, these affinity constants suggest that AHSP impedes the 
incorporation of oxidized αH chains into HbA tetramers, thereby contributing to 
a more stable end state population of reduced HbA following subunit assembly. 
If endogenous reductases are able to reduce AHSP:(met)αH-chain complexes in 
vivo, as the data in Chapter 4 will suggest, then the affinity of AHSP is 
modulated, and reduced αH chains can readily be displaced by βH chains. 
Although AHSP redox reactions have been studied by others (445, 471, 473), 
this specific process has not been directly examined before this work. 
The data presented in this chapter indicate that AHSP is capable of 
binding to αH chains faster than βH chains can bind, and that AHSP has a higher 
affinity for (met)αH chains than ferrous αH chains. Both of these findings are 
consistent with the previously proposed molecular chaperone activity of AHSP. 
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Chapter 4: Changes in αH Chain Properties Following Binding to AHSP 
Several studies have focused on the post-binding effects of AHSP on αH 
chains (442, 443, 445, 471, 473, 502, 508). These effects include increasing αH 
chain resistance to denaturation, aggregation, and precipitation (443), as well 
as structural rearrangements which have been linked to altered αH chain redox 
chemistry and αO globin folding (445, 471, 508, 527). These studies have been 
continued and expanded because the mechanisms underlying these effects are 
incompletely understood, and the results are presented in this chapter. 
 
AHSP and Alpha Chain Oxidation, Hemichrome Formation 
Autooxidation of human HbA is a spontaneous process in which O2 
bound to ferrous heme spontaneously dissociates superoxide (•O2-), leaving the 
iron in the ferric state (518). In vitro studies indicate that this process results in 
the formation of a hemin iron which is coordinated on one side by a histidine 
(the proximal or F8 histidine) and on the other by weakly bound H2O or OH-, 
depending on buffer pH (528, 529). Once the protein is in this oxidized or ferric 
form, the hemin iron can coordinate an additional histidine (the distal, or E7 
histidine) that is located on the opposite side of the heme as the proximal 
histidine (528, 529). This can occur when hemoglobin structure is  perturbed or 
partially unfolded (530). These ―bis-histidyl‖ adducts are called hemichromes, 
and the hemin iron is said to exist in a hexacoordinated state (528, 529). In 
cases involving a reduced or ferrous heme iron, this bis-histidyl 
hexacoordinated state is referred to as a hemochrome. The ferrous and ferric 
forms of pentacoordinate HbA with or without weakly bound water exhibit 
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unique optical absorbance spectral properties (496), as do hemichromes and 
hemochromes (528, 529). 
It has been shown that autooxidation and hemichrome formation can 
occur spontaneously in HbA, particularly under denaturing conditions, and that 
isolated αH and βH subunits undergo these processes at faster rates than 
tetrameric Hbs (186, 531-533). Hemichrome formation is often thought of as a 
detrimental process which precedes protein precipitation in vivo (531). 
However, other roles for hemichrome formation have recently been suggested 
(528, 529). For example, recent work has shown that these conformations are 
intermediates in globin folding pathways (530). 
Although previous studies have made it clear that AHSP appreciably 
accelerates both autooxidation and hemichrome formation in isolated αH chains 
(1, 445, 471, 473), questions as to the reversibility of these processes remain 
unanswered. For example, can αH chains be readily re-reduced following AHSP-
induced oxidation to the ferric bis-histidyl (hemichrome) state? Does re-
reduction result in (1) ferrous bis-histidyl adducts (hemochromes), (2) simple, 
pentacoordinate, and native deoxy ferrous αH chains, or (3) other 
conformations? Is the AHSP-induced ferric bis-histidyl conformation a folding 
intermediate, or is it part of an αH chain degradative pathway as some have 
suggested (444)? These are important questions to answer because the changes 
which AHSP induces render αH chains incapable of O2 transport. Thus, the 
question as to whether or not the redox changes are reversible has a direct 
bearing on the in vivo function of AHSP. 
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Previous findings regarding autooxidation and hemichrome formation 
were first verified using wild-type AHSP, and were then extended by assaying 
the effects of AHSPP30A and AHSPP30W. As shown in Figure 4-1A , incubating 
solutions of isolated, (O2)αH-chains with AHSP results in prominent spectral 
changes. The 541 and 577 nm peaks for (O2)αH chains transition into peaks at 
535 and 565 nm, which represent the hemichrome form of (met)αH-chains 
(Fe3+, bis-histidyl conformation)(528). The observed rates for these transitions 
were measured to be 0.98 hr-1, 0.30 hr-1, and 0.23 hr-1, respectively, for 
AHSP:αH-chain complexes, AHSPP30A:αH-chain complexes, and AHSPP30W:αH-
chain complexes in 100 mM potassium phosphate buffer, pH 7.0 at 37 OC. 
These rates are all significantly faster than the rate of autooxidation of αH 
chains alone (~0.078 hr-1 in 100 mM MES buffer, pH 6.5 at 35 OC (534)). Gell et 
al. (508) have recently reported similar rates for these AHSP mutants, and have 
suggested that the smaller rates observed with the mutants as compared to 
wild-type AHSP are related to the elimination of the cis peptidyl-prolyl 
conformation at position 30 of AHSP (508).  
This work was extended by investigating the reversibility of AHSP-
induced hemichrome formation. Spectra were recorded of ferrous αH chains 
before and after the addition of excess potassium ferricyanide. This reagent 
rapidly oxidizes αH chains to the ferric state (66), and allows the processes of 
oxidation and hemichrome formation to be studied as separate events. 
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Figure 4-1. Autooxidation of AHSP:αH-chain complexes 
Panel A, Plot of AHSP:αH-chain autooxidation absorbance spectra as a function of 
time. Panel B, absorbance changes at 577 nm for αH chains, AHSP:αH-chain complexes, 
AHSPP30A:αH-chain complexes, and AHSPP30W:αH-chain complexes. AHSP:αH-chain 
concentrations were fixed at 20 µM in 100 mM potassium phosphate buffer, pH 7.0 at 
37 OC. Scans were taken every minute for approximately 24 hours. Plots were 
generated using Microsoft PowerPoint and Excel (Microsoft Corporation, Redmond, 
Washington, US). 
 
The spectral differences between (O2)αH chains and (met)αH-chains are 
presented in Figure 4-2, with (O2)αH chains exhibiting strong absorption peaks 
at 541 and 576 nm and (met)αH-chains exhibiting less intense peaks at 500 and 
635 nm (495, 496). In the (met)αH-chain spectrum, the minor peaks at 540 and 
575 nm suggest a small amount of OH- binding to the ferric hemin iron (496). 
Equimolar amounts of AHSP were manually added to this solution of (met)αH-
chains, and peaks at 535 and 565 nm were immediately observed along with the 
disappearance of the 500 and 635 nm peaks. This finding indicates that AHSP 
rapidly induces hemichrome formation (met)αH-chains. The rate of this 
transition was investigated using a stopped-flow device in which absorbance 
changes at 565 nm were followed. Upon mixing 10 µM (met)αH chains with 10 
µM AHSP, a transition with an apparent rate of 50 to 100 s-1 was observed 
(Figure 4-2, inset). This rate is roughly what would be expected for a simple 
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bimolecular binding of (met)αH-chains to AHSP, which is discussed in Chapter 
3 (that is, kobs ≈ k‘AHSP*[AHSP], which means that (10 µM-1s-1)*(10 µM) = 100 s-
1). 
 
Figure 4-2. AHSP-induced αH chain hemichrome 
formation 
The buffer used to record these spectra was 50 mM 
potassium phosphate, pH 7.2 at 22 OC. After preparing 35 
µM αH chains in this buffer and recording the spectrum, a 
two-fold  excess of potassium ferricyanide was added, 
followed by the addition of 35 µM wild-type AHSP. The 
Y-axis of the kinetic trace shown in the inset represents 
the change in absorbance following mixing, and is 
presented using arbitrary units (a.u.) with an offset. Plots 
were generated using Microsoft PowerPoint and Excel 
(Microsoft Corporation, Redmond, Washington, US). 
 
To investigate the reversibility of oxidation and hemichrome formation, 
excess sodium dithionite was added to solutions of AHSP:(met)αH-chain 
complexes, and spectra were recorded immediately following the addition. 
Sodium dithionite is a reducing agent which consumes O2 in aqueous solutions 
and is commonly used to convert ferric Hb to ferrous Hb (66). As is shown in 
Figure 4-3, re-reduction with this reagent does not produce spectra suggestive 
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of a hemochrome, which would be indicated by the emergence of a weak peak at 
529 and strong intense peak at 558 nm, but rather results in a single peak at 
558 nm which is characteristic of pentacoordinated deoxy αH chains (496, 529). 
This finding indicates that the αH chains are in the reduced and native 
deoxygenated form. This experiment was also investigated using a stopped-flow 
device, and re-reduction was found to occur with an observed rate constant of 
approximately 75 s-1 , reflecting the bimolecular rate of reduction of (met)αH-
chains with sodium dithionite (Figure 4-3, inset). Additionally, no hemochrome 
intermediates were observed in these rapid mixing reactions in which broad 
spectral ranges in the Soret region were measured throughout the transition 
using a rapid-scanning stopped-flow device (not shown). 
Collectively, these data indicate that AHSP causes accelerated 
autooxidation and hemichrome formation in αH chains but not hemochrome 
formation when the iron is reduced. These AHSP-induced changes appear to be 
fully reversible, suggesting that AHSP:(met)αH-chain complexes can be readily 
reduced to the ferrous state and are not necessarily part of an irreversible 
protein degradative pathway. Although several alternative hypotheses exist 
regarding the purpose of the AHSP-induced hemichrome conformation, the 
possibility that it is a folding intermediate has not been the subject of any 
comprehensive investigation. The findings in Chapter 3 which indicate 
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Figure 4-3. Reversibility of AHSP-induced αH 
chain hemichromes 
The experimental conditions used to collect these data are 
the same as those described in Figure 4-2. The Y-axis of 
the kinetic trace shown in the inset represents the 
absorbance increase following mixing, and is presented 
using arbitrary units (a.u.) with no offset. A Savitzky-
Golay smoothing filter function (535) was applied to 
reduce signal noise in the inset using OriginPro 8.5.0 
(OriginLab Corporation, Northhampton, Massachusetts, 
US). Unlike the inset in Figure 4-2, the post-mixing 
protein concentrations used in the inset for this figure 
were 2 µM. Plots were generated using Microsoft 
PowerPoint and Excel (Microsoft Corporation, Redmond, 
Washington, US). 
 
a high affinity of AHSP for (met):αH-chains, as well as the recent implication of 
hemichromes as HbA folding intermediates, raise the possibility of a novel 
AHSP mechanism. It may be that AHSP stabilizes ferric αH chain folding 
intermediates until reduction can occur, after which the affinity of AHSP for αH 
chains is lowered, facilitating its displacement by βH chains and allowing HbA 
subunit assembly to proceed rapidly. 
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AHSP and Alpha Chain Hemin Loss and CO-Heme Binding 
Another possible function of AHSP is that it favorably affects heme or 
hemin binding to or dissociation from α chains. Feng et al. (445, 471) and Gell 
et al. (508) showed that AHSP binding to αH chains (1) increases hemin solvent 
accessibility, (2) confers resistance to peroxide-induced hemin damage and 
loss, and (3) reduces the hemin-mediated catalysis of redox chemistry. These 
findings suggest that AHSP might affect the rate of heme binding and/or hemin 
loss from isolated α chains in solution, and these reactions were investigated 
using the methods of Hargrove et al. (153-156, 514). 
In the hemin loss experiments, solutions of αH chains in complex with 
wild-type and mutant AHSP were reacted with excess potassium ferricyanide to 
oxidize the iron to the ferric state. This was done because the rate of reduced 
heme loss is too slow to measure, and the rate for hemin loss is readily obtained 
(156, 170). Immediately following conversion to the met form, a 
myoglobin(Mb)–based hemin loss reagent was added to each solution. This 
hemin loss reagent consists of wild-type sperm whale apoMb (swMbO) with the 
mutations His64Tyr and Val68Phe (156). These replacements enhance the 
stability of swMbO and at the same time alter the spectral properties of the holo 
protein at 600 nm. Following the addition of excess H64Y/V68F swMbO to the 
solutions, hemin is transferred from the (met)αH-chains to the apoMb. The rate 
of increase in the absorbance signal at 600 nm is equal to the rate of hemin loss 
from the (met)αH chains when the concentration of the apoMb is kept high. 
As is depicted in Figure 4-4, AHSP increases the rate of hemin loss from 
αH isolated chains. The observed rates of hemin loss from isolated (met)αH 
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chains, AHSP:(met)αH-chain complexes, AHSPP30A:(met)αH-chain complexes, 
and AHSPP30W:(met)αH-chain complexes are approximately 0.5 hr-1, 0.9 hr-1, 2 
hr-1, and 8.2 hr-1, respectively, in 600 mM sucrose, 200 mM sodium acetate 
buffer, pH 5.5 at 10 OC. While an increase in hemin loss rates was the opposite 
of what was anticipated given that AHSP binding and hemichrome formation is 
thought to stabilize αH chains (443, 445, 471), it is consistent with the finding of 
Feng et al. (445) that the F-helix holding the proximal histidine is disordered in 
AHSP:αH-chain complexes. Also, as these data show, AHSPP30W results in a 
dramatically increased rate of hemin loss. This finding supports the conclusion 
of Gell et al. (508) that Pro30 plays a prominent role in mediating heme-pocket 
structural alterations. In this case, these alterations result in an accelerated rate 
of hemin loss. 
The rate of heme insertion into αO globin was also investigated, again 
using methods reported by Hargrove et al. (153). In these experiments, 
solutions of CO-heme were mixed with αO globin in a stopped-flow 
spectrophotometer at 5 OC to prevent thermal denaturation (153). Upon mixing, 
CO-heme insertion into the αO globin distal pocket can be followed by 
monitoring absorbance increases at 419 nm (the CO-Soret peak) as a function 
of time (153). Data from representative experiments are show in Figure 4-5. In 
agreement with the report of Hargrove et al. (153), the resulting traces for these 
reactions are biphasic. Previous work has demonstrated that the fast phases 
correspond to CO-heme uptake by the distal pocket and the slow phases 
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Figure 4-4. Effects of AHSP on αH chain on hemin loss rates 
Panel A, spectral changes during the course of a representative hemin loss reaction. 
Panel B, normalized time courses at 600 nm which indicate hemin loss rates. These 
experiments were conducted using buffer consisting of 600 mM sucrose, 200 mM 
sodium acetate buffer, pH 5.5 at 10 OC. Although it would have been preferable to study 
these reactions at 37 OC at pH 7.4, hemin loss causes immediate αO globin precipitation 
and solution turbidity which interferes with monitoring the absorbance changes at 600 
nm. Although lowering the temperature to 10 OC minimizes precipitation, these 
reactions are temperature dependent, and the pH was lowered to allow the hemin loss 
reactions to occur on measurable time scales. Each reaction included 6 µM αH chains, 
40 µM swMbO, 30 µM potassium ferricyanide, and 6 µM of either AHSP, AHSPP30A, or 
AHSPP30W. Spectra were recorded every minute for approximately 12 hours. These 
reaction conditions were adapted from Hargrove et al. (154-156). In Panel B, data 
points are indicated by open squares, circles, triangles, and diamonds, with 
exponential fits depicted as lines. Plots were generated using Microsoft PowerPoint 
and Excel (Microsoft Corporation, Redmond, Washington, US). 
 
 
correspond to CO-heme binding to non-specific sites on the protein (153). The 
rate of αH chain formation during these reactions occurs with a second-order 
rate constant of approximately 4 x 107 M-1 s-1 in 50 mM Tris-HCl, 50 mM NaCl, 
pH 8.0 at 20 OC (153). This value agrees with the data presented here, and by 
comparing Figure 4-5A to Figure 4-5B, it is clear that AHSP does not detectably 
affect the rate of CO-heme binding to isolated αO globin. This result, coupled 
with the hemin loss measurements, suggests that AHSP decreases the affinity of 
(met)αH-chains for hemin by approximately 2-fold due to a 2-fold increase in 
the rate of hemin dissociation. 
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Figure 4-5. Effects of AHSP on αO globin CO-heme binding rates 
Panel A, CO-heme uptake by αO globin. Panel B, CO-heme uptake by AHSP:αO-globin 
complexes. All reactions were performed using CO-saturated, 50 mM potassium 
phosphate buffer, pH 7.0 at 5 OC containing small amounts of sodium dithionite. The 
indicated concentrations are post-mixing values, and these traces were plotted with 
offsets. Plots were generated using Microsoft PowerPoint and Excel (Microsoft 
Corporation, Redmond, Washington, US). 
 
 
AHSP and Alpha Chain O2, CO Binding 
The association and dissociation rate constants for O2 binding to αH 
chains in the presence and absence of AHSP were determined by laser flash 
photolysis using established methods (512, 536-538). Complete sets of rate 
constants were measured for O2 binding with the help of Mallory D. Salter 
(John S. Olson Laboratory, Rice University, Houston, Texas, US) and are shown 
in Table 4-1. These data show that wild-type AHSP binding causes a 33% 
decrease in the rate constant for O2 association with αH chains, implying that 
AHSP binding causes little change to the accessibility of the reduced heme 
group. However, the dissociation rate constant for O2 release is increased by 
approximately 272% when αH chains are bound to wild-type AHSP. This 
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increase suggests a weakening of the iron-ligand bond, possibly due to proximal 
strain caused by movement of the F-helix away from the heme plane (445, 471). 
 
Table 4-1. AHSP:αH-chain ligand binding kinetic parameters 
With the exception of the autooxidation studies, all measurements were made using 
100 mM potassium phosphate buffer, pH 7.0 at 22 OC. The rate for αH chain 
autooxidation in the absence of AHSP was taken from Zhou et al. (473). To prevent 
AHSP-induced autooxidation and hemichrome formation, all samples were kept on ice 
and were rapidly brought up to 22 OC before conducting the laser flash photolysis 
experiments. This table was generated using Microsoft PowerPoint (Microsoft 
Corporation, Redmond, Washington, US), and calculations were made using a 
Microsoft Excel spreadsheet that was created by George Blouin (Rice University, 
Houston, Texas, US). 
 
These ideas are supported by the lowered bimolecular rate for CO 
binding to wild-type AHSP:αH-chain complexes. O2 binding to Hbs and Mbs is 
limited primarily by the rate of O2 diffusion into the distal pocket, whereas CO 
binding is limited by the rate of bond formation from within the pocket  (512). 
As a result, k‘CO is a more direct measure of the reactivity of the iron atom and 
restraints imposed by changes in the position of the proximal His(F8) and F-
helix. The decrease in k‘CO and increase in kO2 observed for binding to wild-type 
AHSP:α-chain complexes are consistent with 3-fold decreases in iron reactivity. 
These decreases appear to be caused by constraints imposed by AHSP Pro30, 
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because the values of k‘CO and kO2 for αH chains bound to AHSPP30A and 
AHSPP30W are more similar to those of free αH chains. 
Others have reported that higher O2 dissociation rates correlate with 
increased autooxidation rates (521), and this trend is also observed for the 
AHSP:αH-chain complexes shown in Figure 4-1 and Table 4-1 (473). The net 
effect of these alterations is that the affinity (KA) of αH chains for O2 is 
diminished upon binding to wild-type AHSP and its resistance to autooxidation 
is decreased. 
 
AHSP and Alpha Chain Secondary Structure 
One hypothesis regarding AHSP function is that this protein binds αO 
globins and αH chains, and causes secondary structure changes within these 
subunits (1, 442). Far ultra-violet circular dichroism (CD) spectropolarimetry is 
provides an estimate of the relative amounts of secondary structure that exists 
in a given protein sample (α-helices, β-sheets, random coils)(539). Because 
AHSP and αH chains are almost exclusively α-helical in nature, light at 
wavelengths of 208 and 222 nm can be used in CD measurements to study the 
extent to which these proteins are fully folded (539). 
In one experiment, CD spectra were recorded for samples of 10 µM 
AHSP, 10 µM α chains, and 10 µM AHSP:α-chain complexes. The resulting 
spectra were then plotted together, along with a theoretical trace that was 
generated by adding the individual spectra of AHSP and α chains together. By 
comparing this theoretical trace with the experimentally determined AHSP:α-
chain complex spectrum, it is possible to probe whether AHSP and α chains 
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interact in a way that affects the sum of their secondary structure. Specifically, 
if AHSP binding causes α chains to fold, then stronger CD signals at 208 and 
222 nm are predicted to be observed, giving the observed complex a greater CD 
signal intensity than the theoretical curve. According to the data set forth in 
Figure 4-6, it appears that AHSP does not increase the secondary structure of 
either αO globins or αH chains. These data agree with the work of Feng et al. 
(445, 471) which show that AHSP binding results in several structural 
rearrangements, but that no new α-helices are formed upon complex formation. 
These findings can be contrasted with the recent work of Kumar et al. (527) 
which indicate using CD and NMR data that AHSP stabilizes αO globin in a 
partially folded state. 
 
Figure 4-6. AHSP influence on α chain secondary structure 
Panel A, CD spectra of AHSP, αO globin, and AHSP:αO-globin complexes. Panel B, CD 
spectra of AHSP, αH globin, and AHSP:α-globin complexes. Experimentally recorded 
spectra (solid lines) were obtained in 50 mM potassium phosphate buffer, pH 7.0 at 5 
OC. Theoretical spectra (shaded boxes) in each panel were computed by adding the 
individual AHSP and α chain spectra. AHSP, α chain, and AHSP:α-chain 
concentrations were fixed at 10 µM for these scans. 
 
The main conclusions from these experiments are that (1) AHSP 
destabilizes (O2)αH chains with respect to hemin affinity, (2) AHSP does not 
appreciably alter the secondary structure of either αH chains or αO globins when 
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these proteins are co-incubated together, and (3) the high affinity of AHSP for 
(met)αH chains and reversible AHSP-induced hemichrome formation indicate 
that AHSP may play a role in mediating α chain folding. This last conclusion is 
supported by the recent work of Culbertson et al. (530), who observed a 
(met)Mb hemichrome conformation during unfolding studies. Much like the 
data presented in this chapter, this intermediate exhibited a higher hemin loss 
rate than ferrous Mb, and could rapidly be converted to native and fully 
functional deoxy Mb with the addition of sodium dithionite (530). 
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Chapter 5: Hemoglobin Turriff (αK99E) as a Probe of AHSP Function 
*Much of the information contained in this chapter was previously reported by Yu, 
Mollan et al. (540). The first section contains a review of that work, with subsequent 
sections presenting work that has been performed since that study was published.  
 
Several members of the Mitchell J. Weiss Laboratory (University of 
Pennsylvania, Philadelphia, Pennsylvania, US), John S. Olson Laboratory (Rice 
University, Houston, Texas, US), and Andrew J. Gow Laboratory (Rutgers 
University, Piscataway, New Jersey, US) recently investigated the function of 
AHSP using a set of naturally occurring human αH chain missense mutations, 
which were hypothesized to selectively affect binding to AHSP (540). One of 
these mutations occurs at position 99 of α chains, which is a lysine in wild-type 
subunits but is mutated to a glutamic acid (αK99E) in a hemoglobin variant 
called Hb Turriff (540, 541). The importance of this variant as it relates to 
AHSP function was first discovered by Xiang Yu in the Mitchell J. Weiss 
Laboratory (540). Since that time, I have extended these studies at Rice 
University with the assistance of Jayashree Soman and Eileen Singleton. 
 
Alpha Chain Mutants for Probing AHSP Function 
 
 
In 2004, Feng et al. (445) reported detailed structural information 
regarding the AHSP:αH-chain binding interface, including the identities of all 
the αH chain residues which are thought to interact with AHSP during binding. 
Using this information, Yu et al. (540) conducted a series of literature-based 
searches for previously characterized αH chain variants which contain 
mutations affecting these residues. Several naturally occurring αH chain 
missense mutations were identified, and Yu et al. (540) hypothesized that these 
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mutations might result in altered or impaired interactions with AHSP which, in 
turn, might play a role in the phenotypes associated with these 
hemoglobinopathies. Yu et al. (540) undertook a series of binding studies 
designed to investigate this possibility. 
AHSP and βH chains have been shown to bind αH subunits using a 
similar set of αH subunit amino acids on the G and H helices (445, 471). 
Competition between AHSP and βH chains for the same surface implies that a 
missense mutation which affects AHSP:αH-chain binding is also likely to affect 
interactions at the αH1βH1 (or αH2βH2) dimer interface, making it difficult to 
attribute missense mutation phenotypes to a single set of disrupted 
interactions. Additionally, it is possible for a missense mutation to adversely 
affect αH chains through mechanisms that are unrelated to interactions with 
AHSP and βH chains. For example, a particular mutation may destabilize αH 
chains by causing abnormal or incomplete protein folding. 
With these concerns in mind, Yu et al. (540) selected the following 
naturally occurring αH chain missense mutations for analysis: R31S (Hb Prato), 
K99E (Hb Turriff), K99N (Hb Beziers), H103Y (Hb Lombard), H103R (Hb 
Contaldo), F117S (Hb Foggia), P119S (Groene-Hart), and A130D (Hb 
Yuda)(487, 540-551). Structural work by Feng et al. (445) indicates that 
residues at positions 31, 103, 117, and 119 participate in interactions at the 
αH1βH1 dimer interface, and that mutations corresponding to these positions will 
affect αH1βH1 dimer formation (540). The same structural data indicate that 
residues at positions 99, 103, 117, and 119 participate in AHSP:αH-chain 
interactions, and that that mutations corresponding to these positions will 
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affect AHSP:αH-chain binding (445, 540). Mutations affecting αH chain position 
130 were predicted to have little effect on either interface (445, 540). These 
residue positions, their predicted contacts, and the names of the naturally 
occurring hemoglobinopathies (named after the city of discovery), are given in 
Figure 5-1. 
 
Figure 5-1. Clinically significant αH chain residues 
Panel A, αH1βH1 dimer interface. Panel B, AHSP:αH-chain interface. Panel C, predicted 
binding partner interactions for each interface. In Panels A and B, boxes around each 
label are used in to indicate predicted interactions based on available structural data 
(445, 471). Colors and ribbon and stick forms are the same as those used in Figure 1-8, 
except residues of interest are shown in blue stick form with labels in Panels A and B. 
These panels depict wild-type proteins, except AHSP bears the P30A mutation and a C-
terminal truncation of 11 residues. Drawings were produced using the PyMol Molecular 
Graphics System and PDB entries 1LFL and 1Z8U (DeLano Scientific, Palo Alto, 
California, US)(113, 471). The table in Panel C was adapted from Yu et al. (540) and 
was generated using Microsoft PowerPoint (Microsoft Corporation, Redmond, 
Washington, US). 
 
Three assays were used to investigate AHSP:αH-chain binding: (1) AHSP 
co-expression with αH chains in E. coli and measurement of relative αH chain 
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levels by Western blotting, (2) αH chain production using a eukaryote-based 
protein expression system, with binding to AHSP being investigated by GST 
pull-down methods using GST-AHSP as bait, and (3) αH chain production using 
the same eukaryote-based system, with binding to AHSP being investigated by 
measuring resistance to trypsin digestion (442, 540). Two assays were used to 
assess αH1βH1 dimer formation: (1) electrophoretic mobility shift assays using 
isoelectric focusing and αH chains that were expressed in the eukaryote-based 
protein production system, and (2) βH chain co-expression with αH chains in E. 
coli, with relative αH chain expression yields being approximated by Western 
blot (540).  
The E. coli expression assays described above were performed using 
protocols and vectors that were developed at Rice University (Houston, Texas, 
US). However, all the bench work was done by members of the Mitchell J. 
Weiss Laboratory (University of Pennsylvania, Philadelphia, Pennsylvania, US) 
(540). The underlying premise most of these experiments is that αH chains will 
not be detectably produced unless they are bound to AHSP or βH chains. This 
assumption has been verified by studies showing that in the absence of a 
binding partner, αH chains are too unstable to remain in solution at 25 to 35 OC 
and are readily degraded in E. coli (228, 247, 441). The results of each of these 
assays are summarized in Table 5-1. 
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Table 5-1. Summary of mutant αH chain synthesis, binding evidence 
In this table, ++ indicates normal αH chain production and detection of partner 
binding, + indicates reduced interactions, – indicates no detectable production or 
partner binding, and ND indicates that the presence or absence of interactions were 
not determined. This table was adapted from Yu et al. (540) and was generated using 
Microsoft PowerPoint (Microsoft Corporation, Redmond, Washington, US). 
In agreement with structural predictions, these data reveal that some of 
these mutations (H103Y, H103R, F117S, and P119S) impair both αH1βH1 dimer 
and AHSP:αH-chain complex formation, suggesting at least two plausible 
mechanisms which might explain the anemia, microcytosis, hypochromia, 
Heinz body formation, and other issues observed in individuals bearing these 
mutations (540). Also, as was initially predicted, one mutation (A130D) did not 
detectably disrupt binding at either interface. In contrast, mutations at αH chain 
position 99 (K99E, K99N) selectively impaired AHSP:αH-chain interactions 
while leaving αH1βH1 dimer interface formation unaffected (540). This indicates 
that the clinical features associated with the K99 mutations are likely caused by 
impaired AHSP:αH-chain interactions and not by disruption of the αH1βH1 dimer 
interface (540). 
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Significance of Hb Turriff 
The Hb Turriff (K99E) mutation is of particular interest, because 
previous studies using hemolysates from individuals bearing this mutation 
indicate that this mutation causes αH chain instability leading to excess βH 
chains (540, 541, 552). Consistent with this information, the work of Yu et al. 
(540) indicates that wild-type AHSP does not interact with K99E αH chains, and 
that this disrupted interaction may lead directly to αH chain instability and loss 
of expression in vivo. To test this idea directly, a series of revertant AHSP 
mutants were designed in our laboratory (540). We hypothesized that it should 
be possible to construct an AHSP mutant that would restore binding to and 
stabilization of K99E αH chains (540). This restored binding is predicted to 
facilitate K99E αH chain expression (540). 
As is shown in Figure 5-2, the positively charged ε-amino group of K99 
in αH chains is in close proximity to the terminal atoms of the AHSP Q25 and 
D29 side chains. Mutating the αH chain lysine to a glutamic acid (K99E) 
introduces a negative charge which is expected to cause unfavorable 
electrostatic interactions with the AHSP D29 side chain. To alter the charge on 
the complementary surface of AHSP and potentially restore binding to K99E αH 
chains, AHSP Q25 and D29 were mutated to lysine and arginine residues (four 
single mutants were constructed: AHSPQ25K, AHSPQ25R, AHSPD29K, AHSPD29R). 
These mutant proteins were then assayed to determine whether they could bind 
to and stabilize Hb Turriff αH chains. 
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Figure 5-2. Wild-type, mutant AHSP:αH-chain binding interfaces 
Panel A, wild-type AHSP:αH-chain interface. Panel B, theoretical model of mutant 
AHSP:αH-chain interactions. The αH chain K99 and AHSP Q25 and D29 side chains are 
depicted as CPK-colored sticks, and are predicted to stabilize the AHSP:αH-chain 
interface in wild-type proteins. The αH chain K99E mutation is predicted to disrupt 
these favorable electrostatic interactions. Favorable interactions between the 
negatively charged αH chain E99 side chain and the positively charged AHSP revertants 
K25 and R29 are predicted to restore AHSP:αH-chain heterodimerization. Colors and 
ribbon and stick forms are the same as those used in Figure 1-8. These panels depict 
wild-type proteins, except AHSP bears the P30A mutation and a C-terminal truncation 
of 11 residues. Drawings were produced using the PyMol Molecular Graphics System 
and PDB entry 1Z8U, and Panel B was generated using the mutagenesis wizard that is 
built-in to this software (DeLano Scientific, Palo Alto, California, US)(471). 
 
Yu et al. (540) investigated binding between K99E αH chains and the 
AHSP revertants using: (1) AHSP co-expression with αH chains in E. coli, (2) αH 
chain production using an in vitro wheat germ extract protein expression 
system with the addition of exogenous AHSP, and (3) co-expression of αH 
chains and AHSP in murine erythroleukemia cells. These assays indicated that 
AHSPD29R and AHSPQ25K restored interactions with K99E αH chains and 
increased K99E αH chain expression levels (540). They also suggested that the 
AHSP mutants can stabilize K99E αH chains, whereas wild-type AHSP does not 
appear to interact significantly with this mutant (540).  
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Binding of Hb Turriff αH Chains to AHSP, βH Chains 
To verify the findings of Yu et al. (540), recombinant Hb Turriff was 
produced at Rice University using the methods described in Chapter 2. 
Individual subunits were isolated from these tetramers, and a series of binding 
studies were performed. The behavior of recombinant Hb Turriff during its 
expression and purification was not discernibly different from that of wild-type 
recombinant HbA. Because the recombinant Hb Turriff tetramers contain no 
wild-type αH chains, this observation strengthens the previous conclusion that 
K99E αH chains are able to interact relatively normally with wild-type βH 
chains. 
Two methods were used to confirm that the recombinant K99E αH 
chains are capable of re-binding to wild-type βH chains after separating and 
isolating the individual subunits. First, cellulose acetate electrophoresis was 
conducted on mutant and wild-type subunits. As shown in Figure 5-3 samples 
of native αH chains (lane 1), native βH chains (lane 2), and a mixture of these 
two samples (lane 3, slight excess of βH chains) reveal that these proteins are 
capable of recombining to form HbA. Similarly, when recombinant K99E αH 
chains (lane 4) are mixed with the same sample of native βH chains, they 
recombine to form a band with a similar migration pattern to the one 
corresponding to HbA (lane 5, slight excess of βH chains). The difference 
between the migration patterns of native αH chains and K99E αH chains is 
caused by differences in the isoelectric points of the proteins (541). As is 
apparent from comparisons between lanes 3 and 5, these differences also 
contribute to a slight difference in the migration pattern between the resulting 
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tetramer bands (541). Critically, these data show that K99E αH chains are 
capable of recombining with native βH chains to form Hb Turriff. 
 
Figure 5-3 Electrophoresis of wild-type, mutant 
subunits 
Materials, buffers, and apparatus for this cellulose 
acetate electrophoresis membrane were obtained from 
Helena Laboratories, Incorporated (Beaumont, Texas, 
US). Proteins were stained with Ponceau S stain. The 
following samples were run in accordance with 
manufacturer instructions: native αH chains (lane 1), 
native βH chains (lane 2), a mixture of native αH chains 
and native βH chains (lane 3), recombinant K99E αH 
chains (lane 4), and a mixture of recombinant K99E αH 
chains with native βH chains (lane 5). 
 
 
The second method of confirming that K99E αH chains are capable of 
rebinding to wild-type βH chains involves rapidly mixing the deoxygenated 
subunits and measuring absorbance changes associated with tetramer 
formation. Deoxy subunits exhibit unique absorbance spectra in the Soret 
spectral region depending on whether they are in the high affinity (R) or low 
affinity (T) quaternary state (191). Both monomers and dimers have R-state like 
conformations whereas associated deoxy tetramers exhibit T-state spectra 
(191). The molar extinction coefficients of isolated (deoxy)αH chains and 
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(deoxy)βH chains at 430 nm are 120 and 117 mM-1 cm-1, respectively, and are 
significantly different from the molar extinction coefficient of deoxyHbA 
tetramers at this same wavelength, which is 145 mM-1 cm-1 (494). Differences 
also exist at 445 nm (193). Thus, when separated deoxy subunits are mixed 
together, spectral changes at these wavelengths can be followed as a function of 
time to observe tetramer formation (193). This method was used previously to 
study the kinetics of HbA formation from isolated αH- and βH-chains (201). As 
is shown in Figure 5-4, K99E and wild-type αH chains combine with native βH 
chains to form tetramers at roughly the same rate. 
 
Figure 5-4. (K99E)αH chain association with βH 
chains 
The buffer used for this experiment was 10 mM 
potassium phosphate buffer, pH 7.3 at 20 OC. For the 
reaction involving K99E αH chains, the post-mixing 
concentration values were 5 µM for αH and βH chains, 
and reactions were followed at 430 and 445 nm. For the 
reaction involving wild-type (WT) αH chains, the post-
mixing concentrations were 3 µM for αH and βH chains, 
and reactions were followed at 445 nm only. Traces were 
normalized to total absorbance changes. 
 
Next, two assays were used to investigate the presence or absence of 
binding between K99E αH chains and wild-type human AHSP. Both approaches 
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are based on the experimental framework developed in Chapter 3. First, the 
fluorescence intensity of wild-type AHSP was measured as it was added into 
solutions of 15 µM K99E αH chains, and little or no quenching of AHSP 
fluorescence was observed following each addition (Figure 5-5A). The pattern of 
fluorescence signal increases observed in this experiment resembles the trend 
observed for the titration of wild-type AHSP into βH chains (Figure 3-1C), 
suggesting that there is no interaction between K99E αH chains and wild-type 
AHSP. Second, samples of K99E αH chains were mixed with wild-type AHSP 
using a stopped-flow fluorescence emission spectrophotometer (Figure 5-5B). 
Again, there is no fluorescence quenching of AHSP by K99E αH chains, whereas 
a large and rapid decrease in intensity occurred when the same amount of wild-
type αH chains were mixed with wild-type AHSP.  
 
 
Figure 5-5. Intrinsic fluorescence emission of AHSP, (K99E)αH chains 
The buffer utilized for these experiments was 50 mM potassium phosphate, pH 7.0 at 
21 OC, which had been saturated with CO prior to use. The experimental apparatus 
configurations were the same as those used in Figure 3-1. Plots were generated using 
Microsoft Excel and PowerPoint (Microsoft Corporation, Redmond, Washington, US). 
 
Collectively, the data in Figures 5-3, 5-4, and 5-5 confirm the findings of 
Yu et al. (540) that K99E αH chains are capable of interacting with βH chains to 
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form tetrameric Hb Turriff, but that K99E αH chains are incapable of binding to 
wild-type AHSP. The previous finding that K99E αH chains are not detectably 
expressed in E. coli by themselves or with wild-type AHSP indicates that these 
chains are unstable by themselves. Thus, the clinical features associated with 
this hemoglobinopathy appear to be caused by impaired interactions with 
AHSP (540). 
 
Interactions Between Hb Turriff αH Chains and Wild-Type, Revertant AHSP  
The data reported by Yu et al. (540) indicated that, although K99E αH 
chains are capable of binding to both AHSPQ25K and AHSPD29R, the affinities for 
these interactions appear to be different. Using the methods described in 
Chapter 3, the following sets of binding and dissociation reactions were 
investigated: (1) AHSPQ25K with K99E αH chains, (2) AHSPQ25K with wild-type 
αH chains, (3) AHSPD29R with K99E αH chains, and (4) AHSPD29R with wild-type 
αH chain. These studies confirm the initial findings of Yu et al. (540), and 
extend this work by better defining the electrostatics at the AHSP:αH-chain 
interface. 
The bimolecular association experiments for reactions (1) and (3) are 
shown in Figure 5-6, along with plots of the observed rate constants versus αH 
chain concentrations under pseudo-first order conditions. These data indicate 
that K99E αH chains are capable of rapidly binding to both AHSPD29R and 
AHSPQ25K (Figure 5-6A). However, these binding events are associated with 
smaller fluorescence changes than those that are produced by wild-type 
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AHSP:αH-chain binding under nearly identical conditions (Figure 5-6A). Also, 
small slow phases lasting longer than several hundred seconds were observed in 
these reactions at all concentrations assayed (not shown), indicating either 
cis/trans Pro30 isomerization or slow precipitation of the αH chains. It is clear 
that the affinity of K99E αH chains for AHSPQ25K and AHSPD29R is much less 
than that of wild-type αH chains for wild-type AHSP.  
 
Figure 5-6. AHSPQ25K, AHSPD29R binding to Hb Turriff αH chains 
Panel A, (K99E)αH chain association reactions with wild-type AHSP, AHSPQ25K, and 
AHSPD29R. Panel B, plots used to determine the bimolecular association rate constants 
for the proteins in Panel A. The instrumental configuration for these experiments was 
the same as was used in Figure 3-1, Panel D. Concentrations of AHSP were 250 nM 
post-mixing, and concentrations of αH chains were 8 µM post-mixing in Panel A and 
were varied in Panel B. In both panels, the reactions of wild-type AHSP with wild-type 
αH chains are included for comparison. In Panel A, an offset was used to normalize the 
data for comparison, and a Savitzky-Golay smoothing filter function (535) was applied 
to reduce signal noise using OriginPro 8.5.0 (OriginLab Corporation, Northhampton, 
Massachusetts, US). Plots generated using Microsoft Excel and PowerPoint (Microsoft 
Corporation, Redmond, Washington, US). 
 
Because the AHSP revertants involve mutations to residues that are in 
close proximity Pro30, it is plausible that the slow phases observed during 
bimolecular association are related to structural alterations and/or altered cis-
trans peptidyl-prolyl isomerization. Thus, apart from the predicted electrostatic 
changes that these mutations could induce, there may also be structural 
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rearrangements and changes in the cis/trans equilibrium. Consistent with this 
idea, it was found that wild-type αH chains are capable of binding to both 
AHSPQ25K and AHSPD29R (Figures 5-7A and 5-7B), and very slow phases are still 
observed. Wild-type αH chain binding reactions are associated with strong 
fluorescence changes that are similar to those seen with wild-type AHSP:αH-
chain binding. This finding suggests that the disrupted binding between wild-
type AHSP and K99E αH chains is not due exclusively to charge repulsion 
between D29 AHSP and E99 αH chain side chains. If this were the case, wild-
type αH chains would be predicted to bind poorly to the revertant AHSP 
mutants, due in this case to repulsion between the positively charged (K99) αH 
chain and AHSP R29 side chains. Thus, these data suggest that structural 
elements in the loop separating AHSP helices 1 and 2, as well as electrostatics, 
are important determinants of αH chain binding. 
The displacement reactions for wild-type and (K99E) αH chain 
interactions with wild-type and mutant AHSP were also measured, and the 
resulting data are presented in Figure 5-8. The dissociation reactions involving 
AHSPD29R:(K99E)αH-chain and AHSPQ25K:(K99E)αH-chain complexes were 
found to be much more rapid than those for wild-type AHSP:αH-chain 
complexes (Figures 5-8A and 5-8B). In the case of the AHSPQ25K:(K99E)αH-
chain complex, no displacement reaction was observed at 250 nM 
concentrations and the fluorescence of the AHSPQ25K:(K99E)αH chain complex 
was similar to that of the AHSP mutant alone. Raising the post-mixing 
concentrations of the AHSPQ25K:(K99E)αH-chain mixture to 6 µM did result in 
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small and rapid fluorescence increases after mixing with (CO)βH chains (Figure 
5-8A, inset). Thus, some AHSPQ25K:(K99E)αH-chain complex did form 
 
Figure 5-7. AHSPQ25K, AHSPD29R binding to wild-type αH chains 
Panel A, wild-type αH chain association reactions with wild-type AHSP, AHSPQ25K, and 
AHSPD29R. Panel B, plots used to determine the bimolecular association rate constants 
for the proteins in Panel A. The instrumental configuration for these experiments was 
the same as was used in Figure 3-1, Panel D. Concentrations of AHSP were 250 nM 
post-mixing, and concentrations of αH chains were either fixed at 8 µM post-mixing in 
Panel A or were varied as indicated in Panel B. In both panels, the reactions of wild-
type AHSP with wild-type αH chains are included for comparison. In Panel A, an offset 
was used to normalize the data for comparison, and a Savitzky-Golay smoothing filter 
function (535) was applied to reduce signal noise using OriginPro 8.5.0 (OriginLab 
Corporation, Northhampton, Massachusetts, US). Plots were generated using 
Microsoft Excel and PowerPoint (Microsoft Corporation, Redmond, Washington, US). 
 
at this higher concentration, but clearly the KD for complex formation is high. 
This conclusion is consistent with the bimolecular association data presented in 
Figure 5-6B. Using those data, the Y-intercept of the AHSPQ25K trend line 
provides an estimate for the dissociation rate constant of 17 ± 2 s-1, which is a 
much faster than the rate of dissociation of wild-type AHSP:αH-chain 
complexes (~.19 s-1, see Chapter 3). This value was used as the basis for 
generating the theoretical replacement reaction curve shown in Figure 5-8B 
(inset, dashed line).  
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Figure 5-8. (K99E)αH chain, AHSP revertant displacement reactions 
Panel A, AHSPQ25K, AHSPD29R dissociation from (K99E)αH chain complexes. Panel B, 
plot of the observed rates of AHSPD29R:(K99E)αH-chain dissociation at various 
concentrations of βH chains, and an analogous theoretical curve for 
AHSPQ25k:(K99E)αH-chain dissociation (inset). Panel C, AHSPQ25K, AHSPD29R 
dissociation from wild-type αH chain complexes. Panel D, plot of the observed rates of 
AHSPQ25K:αH-chain and AHSPD29R:αH-chain dissociation at various concentrations of 
βH chains. The instrumental configuration for these experiments was the same as was 
used in Figure 3-1, Panel D. In Panels A and C, the concentrations of AHSP:αH-chain 
complexes were 250 nM post-mixing and the concentrations of βH chains were 8 µM 
post-mixing. In the inset of Panel A, AHSP:αH-chain complexes were 6 µM post-
mixing. In all panels, the reactions involving wild-type AHSP:αH-chain dissociation are 
included for comparison. Plots were generated using Microsoft Excel and PowerPoint 
(Microsoft Corporation, Redmond, Washington, US). 
 
The displacement reactions involving wild-type αH  chain dissociation 
from AHSPD29R and AHSPQ25K were also investigated, and the data are shown in 
Figures 5-8C and 5-8D. In both cases, dissociation was more rapid than what 
was observed for wild-type AHSP:αH-chain complex dissociation, although 
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neither reaction was as rapid as the dissociation of AHSPD29R:(K99E)αH-chain 
and AHSPQ25K:(K99E)αH-chain complexes. The kinetic parameters calculated 
from these reactions are presented in Table 5-2.  
 
 
Table 5-2. Kinetic parameters for αH chain, AHSP revertant interactions 
The data used in these calculations were collected using the same instrumental 
configuration as described in Figure 3-1D. Rate parameters and dissociation 
equilibrium constants for these reactions were calculated using the same methods that 
were used in Chapter 3. However, AHSPQ25K:αH-chain dissociation could not be 
measured using these techniques due to its low affinity. In this case, the dissociation 
rate constant was estimated from the bimolecular association studies shown in Figure 
5-6, and k‘αβ was not determined (ND). Reactions involving these proteins were done 
twice, and the numbers provided in this table represent averages of the obtained 
values: AHSPQ25K:(K99E)αH-chain complexes and AHSPD29R:(K99E)αH-chain 
complexes. Reactions AHSPQ25K:αH-chain complexes and AHSPD29R:αH-chain 
complexes were only measured once. Calculations were done using Microsoft Excel 
and the table was constructed using Microsoft PowerPoint (Microsoft Corporation, 
Redmond, Washington, US). 
 
Both the bimolecular association and the displacement studies of these 
proteins show that both AHSPQ25K and AHSPD29R can bind Turriff and wild-type 
αH chains, with AHSPD29R exhibiting tighter binding to both αH  chains. These 
data are in full agreement with the report of Yu et al. (540), which indicated 
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that AHSPD29R was more effective at restoring binding to (K99E)αH chains than 
AHSPQ25K. These results also show that: (1) (K99E) αH  chains do not detectably 
bind to wild-type AHSP, and that these disrupted interactions can plausibly 
account for the clinical features associated with Hb Turriff, (2) electrostatics 
involving αH  chain K99 play a prominent role in binding to wild-type AHSP, 
and when these interactions are disrupted by the K99E mutation, they can be 
restored by compensatory AHSP mutations which similarly effect electrostatics, 
and (3) electrostatics are not the only factor involved with binding, because the 
loop separating AHSP helices 1 and 2 appears to mediate conformational 
changes which significantly affect binding. 
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Chapter 6: Co-Expression of AHSP with Recombinant HbA 
 
This chapter describes the construction of a novel rHb expression system 
that is useful for assaying whether the co-expression of AHSP with HbA in E. 
coli results in increased HbA expression yields. This work was done with the 
assistance of Eileen Singleton, Jayashree Soman, and Neil Varnado of the John 
S. Olson Laboratory, and Mary Harrison of the George N. Bennett Laboratory at 
Rice University. 
 
Expression System Construction 
Optimizing rHb production from E. coli-based heterologous protein 
expression systems involves investigating a diverse set of variables relating to 
molecular biology, fermentation conditions, and downstream processing 
methods (252, 254-265, 267-276). Although significant work has already been 
done in this area (211, 225, 226, 282, 283), recent efforts have shown that the 
co-expression of hemin transport proteins with rHbs in E. coli helps to bolster 
expression yields (39, 213, 216, 436, 437, 553-555). Available information 
regarding AHSP function suggests that it might be of similar utility. 
AHSP has been co-expressed with αH chains by several groups using 
several different expression systems (440-442, 445, 471, 540). It has also been 
co-expressed with human-bovine hybrid rHb in E. coli (556). Additionally, 
AHSP has been expressed in a wheat germ transcription and translation system 
designed to study HbA subunit assembly (442). Although these studies have 
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consistently indicated that AHSP facilitates αH chain expression, there remains 
very little published work addressing whether this protein can be used to 
increase production yields of tetrameric rHb.  
Because GST has a molecular mass that is more than twice that of AHSP, 
overexpressing this protein along with AHSP is predicted to cause a significant 
strain on cellular resources. As an initial step towards optimizing the co-
expression of AHSP with rHb, the gst gene was removed from the N-terminus 
of the ahsp gene in pre-existing expression vectors. To accomplish this, the 
ahsp gene was cloned into a vector, pBAD33, that was provided by George N. 
Bennett (Rice University, Houston, Texas, US)(557). This vector was chosen as 
an AHSP expression plasmid for the following reasons. First, AHSP expression 
can be induced with exogenous L-arabinose, which is an inexpensive alternative 
to IPTG (557). Second, AHSP expression levels can be fine-tuned by varying the 
amount of inducer added to the culture media (557). Third, high-yield 
heterologous protein expression using pBAD vectors has previously been well 
established (557). Fourth, pBAD33 has a selectable marker and an origin of 
replication which are compatible with those of other rHb expression vectors 
(557). The HbA expression vector rHb 0.0 was selected to be used in 
conjunction with pBAD33, since this plasmid has been used extensively in 
previous rHb expression studies (211, 225, 226, 248, 250). The features of each 
of these plasmids are depicted in Figure 6-1. 
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Figure 6-1. AHSP, rHb co-expression vectors 
Panel A, AHSP expression vector. Panel B, HbA expression vector. HbA and AHSP 
production is induced using IPTG and L-arabinose, respectively. The selection of these 
disparate promoters allows for HbA expression to be studied in the presence and 
absence of AHSP expression. Although not depicted in Panel B, the α and β globin 
genes are transcribed into a single mRNA molecule which contains two ribosome 
binding sites. This allows each globin to be translated independently from the other. 
This figure was produced using Microsoft PowerPoint (Microsoft Corporation, 
Redmond, Washington, US)(557). 
 
Following the construction of pBAD33-AHSP, Top10 cells were obtained 
from Invitrogen Corporation (Carlsbad, California, US) and co-transformed 
with pBAD33-AHSP and rHb 0.0. This strain of cells, which will be referred to 
as E. coli AH1, cannot metabolize arabinose due to an AraD disruption (558). 
This gene encodes L-ribulose-5-phosphate 4-epimerase, which is partly 
responsible for metabolizing arabinose once it is taken up by the cells. Its 
disruption in this strain prevents digestion of the AHSP inducer during the 
experiments described in the next section (558).  
 
Co-Expression of AHSP with rHb  
E. coli AH1 were used to assay the effects of the presence and absence of 
AHSP expression on HbA production using methods first developed by Antony 
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J. Mathews (Somatogen Incorporated, subsequently acquired by Baxter 
Healthcare Corporation)(39, 226). Briefly, a 5 mL pre-culture of sterile LB 
media containing 10 µg/mL tetracycline and 25 µg/ml chloramphenicol was 
inoculated with a single colony of E. coli AH1 and grown overnight at 37 OC with 
225 RPM shaking. The next morning, this entire culture was used to inoculate a 
1 L Erlenmeyer flask containing 150 mL of sterile 2X TB media containing the 
same concentrations of antibiotics. The growth of this culture was monitored 
until the optical absorbance at 600 nm reached 0.8 to 1.0, at which time the 
temperature was dropped to 32 OC and 25 µM exogenous hemin was added. 
Then, 2.5 mL of this culture was added to each of ten, pre-sterilized glass test 
tubes. A titration of arabinose ranging from 0.0005% to 0.5% (m/v) was then 
added to the culture tubes, which were allowed to grow overnight before being 
harvested approximately 15 hours post-induction. During this phase of the 
experiments, IPTG was not added to the cultures to induce HbA production, 
because doing so was found to result in an appreciable amount of insoluble 
protein aggregates. Instead, leaky expression from the Ptac rHb promoter was 
used to produce rHb. 
The cells harvested from each tube were resuspended in phosphate 
buffered saline (PBS) solution (140 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 2 
mM KH2PO4, pH 7.4 at 20 OC) that had been bubbled with CO and chilled to 4 
OC prior to use. Then, absorbance spectra were recorded after normalizing each 
sample for cell density as approximated by optical absorbance at 700 nm. In 
these spectra, peaks in the Soret regions begin to emerge as increasing amounts 
of hemoglobin are produced (39), and the first derivatives of these spectra 
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provide an estimate of relative hemoprotein expression levels. The peak-to-
trough distances of these traces can be plotted against arabinose concentration 
to ascertain the effects of various levels of AHSP induction. Representative data 
from these experiments are presented in Figure 6-2. 
 
Figure 6-2. Co-expression of AHSP with rHb in E. coli 
Panel A, first derivative spectra in the Soret region of E. coli AH1 under conditions of 
variable AHSP induction. Panel B, plot of arabinose concentration against relative 
hemoprotein production levels. In Panel A, a Savitzky-Golay smoothing filter function 
(535) was applied to reduce signal noise using the Cary WinUV Bio Pack software 
(Agilent Technologies, Incorporated, Santa Clara, California, US). Plots were generated 
using Microsoft Excel and PowerPoint (Microsoft Corporation, Redmond, Washington, 
US). 
 
Although this method does not discern between αH chain, AHSP:αH-
chain complex, βH chain, and HbA production, it does report on total 
hemoprotein overexpression levels. As shown in Figure 6-2, AHSP appears to 
increase expression yields as long as its induction is weak. Under conditions of 
stronger AHSP induction, however, hemoprotein expression appears to 
diminish. Although the underlying mechanism giving rise to this trend is 
unclear, it is likely that high-level AHSP expression inhibits HbA production by 
binding to free αH chains and competitively inhibiting their association with βH 
chains. One effect might be that the resulting free βH chains precipitate, causing 
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a decrease in Soret signal peak intensity. Although these assays are preliminary, 
they reveal that AHSP co-expression may be useful in rHBOC production 
efforts. 
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Chapter 7: Characterization of HbF Toms River 
 
*Much of the prose, figures, and references that appear in this chapter were taken from 
Crowley, Mollan, et al. (559). The portions reproduced here are those which were 
written by the second author or have been paraphrased based on background case 
information provided by the co-authors of this study (personal communication). 
 
The following information was discovered as a result of several studies of 
a novel hematological condition that was found in a newborn baby from Toms 
River, New Jersey, US. This work was done in collaboration with Moira A. 
Crowley (Case Western Reserve University), Osheisa Y. Abdulmalik (The 
Children‘s Hospital of Philadelphia), Andrew Butler (Rutgers University), Emily 
F. Goodwin (University of Alabama), Arindam Sarkar (Rice University), 
Catherine A. Stolle (The Children‘s Hospital of Philadelphia), Andrew J. Gow 
(Rutgers University), John S. Olson (Rice University), and Mitchell J. Weiss 
(Children‘s Hospital of Philadelphia).  
 
Background, Case Information 
Physicians from several institutions recently treated a full-term female 
neonate who was born with cyanosis (―a bluish or purplish discoloration (as of 
skin) due to deficient oxygenation of the blood‖ (560)). Physical examinations 
of this newborn revealed that the baby had normal APGAR scores (―an index 
used to evaluate the condition of a newborn infant...‖ (560)). Additionally, the 
chest X-ray, echocardiogram, and laboratory tests for various metabolic and 
infectious diseases did not reveal the presence of any known abnormalities or 
infections. There was also no evidence of elevated methemoglobin levels, which 
is a common cause of blue baby syndrome (561-563). Apart from the apparent 
115 
cyanosis, healthcare workers described the patient as ―a happy blue baby‖ that 
was ―clinically well.‖ 
Several findings indicated that this patient‘s unusual clinical 
presentation could be attributed to a hemoglobinopathy. First, the patient‘s 
symptoms self-resolved within two months following her release from the 
hospital on day six of life, and the patient‘s father apparently suffered from the 
same condition. Like his daughter, his symptoms disappeared within a few 
months post-birth. Second, clinical diagnostics and laboratory data from 
several blood tests indicated abnormalities relating to the patient‘s hemoglobin 
(not shown). Third, the timing of the disappearance of the cyanosis coincided 
with a process called globin switching (118, 129, 130, 564). During this process, 
fetal hemoglobin (HbF) production is dramatically decreased and its synthesis 
is replaced by adult hemoglobin (HbA) production in the two month period 
following birth (131). These observations prompted researchers to posit an 
etiology related to Fetal Hemoglobin (HbF). 
Sequencing of the patient‘s globin alleles revealed the presence of a 
heterozygous missense mutation in the Gamma G (Gγ) globin gene (HBG2, 
NCBI Accession NM_000184.2)(114). Specifically, a G to A substitution at 
nucleotide position 202 (c.202G>A) replaces valine with methionine at codon 
68 or amino acid 67 in the post-translationally processed Gγ chain product. This 
mutation will be referred to as the γ V67M mutation throughout this chapter. 
By convention, the name of this mutant HbF has been designated ―Hemoglobin 
Toms River‖ (or HbF Toms River). BLAST searches for the γ V67M mutation 
were conducted to ensure that this mutation had not already been reported, and 
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these studies indicated that Hemoglobin Toms River was a novel fetal Hb 
variant. 
 
Functional Studies of Hemoglobin Toms River 
In order to understand the mechanism(s) underlying the clinical 
phenotype caused by Hemoglobin Toms River, it is important to know where 
the γ V67M (E11) mutation occurs within the structure of HbF. This is because 
mutations occurring at the αH1γH1 dimer interface, for example, suggest a 
different set of functional consequences than mutations in the distal pocket. As 
a preliminary step, a molecular model of HbF Toms River was generated and 
compared to wild-type protein. 
Figure 7-1A shows an X-ray crystal structure of wild-type human 
(deoxy)HbF (133). The residue labeled 67Val is mutated to a methionine in HbF 
Toms River. Figure 7-1B shows a structure which was modeled to depict this 
mutation. Position 67 (E11) is located in the distal pocket adjacent to bound 
ligands and the iron atom. Because methionine is significantly larger than 
valine (by approximately 32 atomic mass units (amu)), and because it has the 
potential to project further into the ligand binding pocket than valine, it is clear 
that the Toms River mutation is likely to affect O2 binding and transport. 
Additionally, methionine side chains are known to participate in biochemically 
significant and potentially injurious redox chemistry (565-567). These 
observations suggested several functional assays. 
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Figure 7-1. Wild-type HbF, HbF Toms River Structures 
Panel A, native HbF γ subunit showing valine at position 67 (PDB 1FDH)(133). Panel 
B, predicted structure of HbF Toms River γ subunit showing the mutant methionine 
inserted into the wild-type structure at position 67. In both panels, γ subunits are 
depicted using yellow ribbons.  The planar heme group and its associated histidine are 
shown using red and yellow stick models, respectively. The iron atom is shown as an 
orange sphere. Oxygen enters the heme pocket as indicated by the blue arrow and 
binds iron on the upper face of the heme ring opposite to the associated histidine. The 
residues at position 67 are shown using spheres, with blue indicating the additional 
methionine atoms that hinder oxygen access to the iron atom in the center of the heme 
ring. The insets show the native valine and mutant methionine in stick and spherical 
dot format to indicate the size difference between the amino acids. Both panels were 
constructed using the PyMOL Molecular Graphics System, with the HbF Toms River 
mutation being modeled using the mutagenesis wizard that is built-in to this software 
(DeLano Scientific, Palo Alto, California, US). 
 
Preliminary experiments were conducted in the Mitchell J. Weiss 
Laboratory (University of Philadelphia, Philadelphia, Pennsylvania, US) using 
hemolysates that were obtained from whole blood samples from the patient. 
These experiments were significantly informed by literature-based research 
which revealed that the V67M mutation was known to occur in rare instances in 
βH chains of adult human HbA (HbA Bristol-Alesha)(568-571). Because studies 
of HbA Bristol-Alesha have shown that the methionine at position 67 is 
spontaneously and post-translationally oxidized to an aspartate residue, the 
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presence of Asp67 in the γ chains of HbF Toms River was investigated. Mass 
spectrometry data provided evidence for the existence of this conversion event. 
These data are discussed further by Crowley, Mollan, et al. (559), but they were 
not obtained at Rice University and will not be reviewed here. 
Because the patient ceased producing HbF Toms River, it became 
necessary to produce this protein using recombinant technology in order to 
continue studies of its functional properties. The methods described in Chapter 
2 were used to produce and purify both wild-type HbF and HbF Toms River. 
Using the resulting proteins, autooxidation studies were performed for wild-
type and mutant HbF using previously established methods (339, 473, 572, 
573). Data from these experiments are presented in Figure 7-2, and they 
suggest that the Toms River mutation does increase the apparent rate of HbF 
autooxidation by approximately two- to three-fold at 37 OC in air equilibrated 
buffer, but this process is still very slow and unlikely to account for the patient‘s 
phenotype. 
Laser flash photolysis techniques were then used to investigate the effect 
of the Toms River mutation on the rate of O2 binding. The association (k‘O2) and 
dissociation (kO2) rate constants for the last step of O2 binding to the individual 
globin subunits in both proteins were measured using previously established 
methods (112, 512, 538). The V67M mutant was found to bind O2 and CO ~25 
times more slowly than wild-type subunits (Table 7-1). In contrast, this 
mutation was found to have little effect on the rate of O2 release (kO2) from 
saturated oxygenated HbF. Consequently, the mutated γ subunits in the high-
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affinity state (R) of HbF has a ~30-fold increased P50 (~12 µM or ~7 mm Hg) 
compared to that of wild-type R-state γ subunits.  
 
Figure 7-2. Autooxidation of wild-type, mutant HbF 
Panel A, spectra at the start of the autooxidation reaction and 1000 minutes into the 
reaction for wild-type HbF. Panel B, time course of the reaction as followed at 577 nm. 
Reactions used air equilibrated 100 mM potassium phosphate buffer, pH 7.4 at 37 OC. 
Autooxidation was followed at 577 nm, with absorbance signals at this wavelength 
plotted against time for wild-type HbF and HbF Toms River. Panel B data points are 
shown with exponential fits overlaid for clarity. Plots were generated using Microsoft 
Excel and PowerPoint (Microsoft Corporation, Redmond, Washington, US). 
 
 
Table 7-1. Kinetic parameters for ligand binding to wild-type, mutant HbF 
Reactions were studied using 100 mM potassium phosphate buffer, pH 7.0 at 20 OC. 
Parameters marked with an asterisk were taken from Birukou et al. (500) and are 
included as a general reference. The data for wild-type HbF roughly agree with the 
values reported by Noble et al. (574). This figure was produced using Microsoft 
PowerPoint (Microsoft Corporation, Redmond, Washington, US). 
 
These findings partially explain the cyanosis observed in the patient. The 
effects of this mutation on the ligand binding rates clearly alters the O2 affinity 
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of HbF Toms River, likely resulting in impaired O2 transport. Also, the post-
translational conversion of methionine to aspartic acid is predicted to 
destabilize the Hb tetramer.  The phenotypes associated with Hb Bristol-Alesha 
(mainly hemolytic) and Hb Toms River (mainly cyanotic) may be related to 
these two proteins having different rates of methionine to aspartate conversion. 
Also, Hb Bristol-Alesha affects one of two β globin alleles, whereas Hb Toms 
River is present in one of four γ globin genes. In future work, the John S. Olson 
Laboratory (Rice University, Houston, Texas, US) and Abdu I. Alayash 
Laboratory (Center for Biologics Evaluation and Research, Food and Drug 
Administration, NIH campus, Bethesda, Maryland, US) intend to compare the 
properties of recombinant HbA and HbF tetramers containing E11 valine to 
methionine substitutions in order to resolve questions of this type.  
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Chapter 8: Summary of Findings 
 
Prior to this work, the association and dissociation rate constants for 
AHSP:αH-chain interactions had not been reported. The kinetic parameters 
determined from these experiments show that AHSP binds to αH chains more 
rapidly than βH chains bind to αH chains, but that βH chains have a higher 
affinity. This explains previous reports of others that AHSP is competitively 
displaced from AHSP:αH-chain complexes by βH chains. It is also consistent 
with a molecular chaperone function of AHSP. This idea is supported by the 
finding that AHSP has a relatively high affinity for (met)αH chains, which are 
unstable when free in solution, and that co-incubation of AHSP with αH chains 
causes them to adopt a reversible hemichrome conformation that has recently 
been implicated as a globin folding intermediate. All these data are consistent 
with the Hb Turriff studies which show that AHSP helps to stabilze αH chains 
during in vivo HbA biosynthesis. 
Although wild-type AHSP does not appear to dramatically affect heme 
affinity and αH chain secondary structure (though slight differences do exist in 
the case of hemin loss), it is clear from the studies involving AHSP Pro30 
mutants and (K99E)αH chains that the loop separating AHSP helices 1 and 2 is 
critical to AHSP function, both because of electrostatic interactions and 
structural conformational issues. This is evident in the studies of the impact of 
AHSP and the Pro30 mutants on ligand binding kinetics as well. Also, these 
findings confirm and extend the NMR work of others, which originally 
established the existence of cis and trans AHSP conformations, with work here 
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demonstrating the impact of this isomerization event on the rates of AHSP 
binding.  
The finding that AHSP helps with HbA production in E. coli is consistent 
with what others have found regarding the co-expression of AHSP with αH 
chains alone. Although the HbA expression yields gained by co-expressing 
AHSP with both αH and βH chains are modest, it is clear that this is an effective 
strategy that is worth pursuing in future studies. 
Lastly, using several of the methods that were used to study AHSP 
function, the HbF Toms River mutation was studied, and several plausible 
mechanisms have been uncovered that may explain the clinical features of this 
hemoglobinopathy. 
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